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Abstract 
 
G protein-coupled receptor 81 (GPR81) is abundantly expressed in adipocytes 
where activation by the endogenous ligand lactate inhibits lipolysis. GPR81 is 
also found in non-adipose tissue but the receptor’s function here is currently 
not fully understood. In vivo infusion of specific GPR81 agonist, AZ’5538, has 
been shown to increase blood pressure (BP). We therefore hypothesised a 
role for GPR81 in the cardiovascular and renal systems with the aim to 
examine the in vivo effects of AZ’5538 on renal haemodynamics and to localise 
expression of the receptor within the kidney and vasculature. Initially, we found 
expression of Gpr81 mRNA in the whole aorta, mesenteric and renal arteries 
of C57Bl/6JCrl mice using end point PCR. Then, using RNAscope in situ 
hybridisation in Gpr81-/- mice and wildtype (WT) littermates we found 
expression in the kidney medulla, arterioles of the glomerulus and smooth 
muscle cells of the vasculature. WT and Gpr81-/- mice were terminally 
anaesthetised, the carotid artery cannulated and renal blood flow (RBF) or 
perfusion measured by a Doppler ultrasound probes during IV infusion of either 
AZ’5538 or vehicle. Infusion of AZ’5538 significantly increased BP and 
reduced HR, RBF and cortical and medullary perfusion. Activation of GPR81 
in vivo also decreased glomerular filtration rate with no change in ion excretion. 
All of these effects were absent in Gpr81 null mice. Plasma endothelin-1 (ET-
1) was increased in mice treated with AZ’5538 with no change in whole kidney 
and aorta homogenate levels, suggesting release of ET-1 into the circulation. 
Prior treatment with BQ-123 (endothelin-A receptor antagonist) prevented the 
AZ’5538 mediated blood pressure increase whereas BQ-788 (endothelin-B 
receptor antagonist) had no effect. We showed Gpr81 expression in vascular 
smooth muscle, glomerulus and medulla of the mouse kidney. In vivo, GPR81 
activation influences cardiorenal haemodynamics in an endothelin-A receptor 
mediated manner by stimulating circulating ET-1. The sensitivity of the renal 
circulation to GPR81 activation may become physiologically significant when 
circulating lactate, the endogenous ligand of GPR81, concentration rises, as 
can occur in ischemic renal disease.  
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Lay summary 
 
High blood pressure, also known as hypertension, affects 1 in 4 adults 
worldwide and is the largest single known risk factor for cardiovascular disease 
and related disability. Understanding what causes hypertension and finding 
potential targets is important for treating the disease in the future. Lactate is a 
molecule which is formed when the body does not have enough oxygen. 
Lactate can bind to the receptor GPR81 which is found mainly in fat but also 
throughout the body. We currently do not know what the function of GPR81 is 
in the heart and kidney. A drug which is similar to lactate, AZ’5538, has been 
designed to bind to GPR81. This drug has been found to increase blood 
pressure, but it is not understood why. In my thesis I found that AZ’5538 not 
only increases blood pressure but also prevents the flow of blood to the kidney 
by causing blood vessels to constrict. We found that GPR81 is found in blood 
vessels throughout the body as well as in the small arteries in the kidney. This 
receptor could be important in controlling blood pressure as well as in diseases 
where lactate levels are high.  
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Chapter 1 - Introduction 
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1.1 Renal control of blood pressure 
Currently, 25% of the worldwide population suffer from high blood pressure 
(hypertension)1, which is classified as pressures over 140/90 mmHg. 
Hypertension is also the major modifiable risk factor for the majority of 
cardiovascular diseases including cardiomyopathy, stroke, atherosclerotic 
vascular disease, congestive heart failure and chronic kidney disease (CKD)2–
4. Control of blood pressure is complex and involves integration of multiple 
regulatory pathways (e.g. neural, hormonal, immune and paracrine) 
throughout many key cardiovascular control systems of the body5. Although 
controversial, the Guyton hypothesis places renal control of salt and 
extracellular fluid volume at the centre of long-term blood pressure 
homeostasis6. The mechanism known as pressure natriuresis relates to 
changes in renal perfusion pressure which alters sodium reabsorption by the 
proximal tubule to regulate blood pressure homeostasis7. Although the 
mechanisms of the acute pressure natriuresis response are still not fully 
understood, pressure natriuresis is abnormal in almost every model of 
hypertension7, confirming the importance of this response in blood pressure 
stabilisation.   
 
1.2 Renal haemodynamics 
Renal blood flow (RBF) is tightly autoregulated in the kidneys by mechanisms 
of vasoconstriction and dilation by the large arteries and smaller arterioles of 
the kidneys to allow a relatively constant flow rate of blood and GFR in the face 
of fluctuations in arterial pressure. An overview of the renal vasculature is 
shown in Figure 1.1. Autoregulation is essential to stabilise GFR, and therefore 
the filtered load of different solutes to keep concentrations of electrolytes 
stable even with changes in blood pressure. It is also important to prevent 
glomerular capillaries from barotrauma by stopping increases in blood 
pressure reaching these delicate renal vessels. Damage to these capillaries 
can lead to glomerulosclerosis due to hypertrophy and the thickening of 
arteriole walls and  results in an inability of the kidneys to properly filter8,9.  
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Figure 1.1 An overview of the renal vasculature 
Adapted from Openstax Anatomy and Physiology textbook10 under the license 
https://creativecommons.org/licenses/by/4.0/ to redistribute. Blood enters the kidney 
through the renal artery which divides into the segmental arteries and further branches 
to form the interlobar arteries which pass through the renal columns into the cortex. 
The interlobar arteries branch into arcuate arteries, cortical radiate arteries and finally 
into afferent arterioles. After passing through the renal corpuscle, the capillaries exit as 
efferent arterioles which then form a network around the nephron as peritubular 
capillaries before returning to the venous system.  
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There are two main mechanisms of renal haemodynamic autoregulation which 
are responsible for controlling RBF and GFR with either rapid or slower 
increases in systemic blood pressure. The first mechanism, which responds 
with rapid compensation in a matter of seconds, is the myogenic response9. 
Here, the preglomerular afferent arterioles constrict in response to an increase 
in transmural pressure11. Vasoconstriction of these arterioles is due to an influx 
of intracellular calcium initiating depolarisation of vascular smooth muscle cells 
(VSMC)12. In response to slower increases in blood pressure or for increases 
which are not fully compensated by the myogenic response, tubuloglomerular 
feedback takes place. In this state there is increased glomerular capillary 
pressure, increased GFR and inhibition of sodium reabsorption in the proximal 
tubule. The macula densa cells of the distal tubule sense increases in sodium 
chloride concentration (which indicates increase flow) which causes release of 
adenosine to initiate contraction of the VSMC of afferent arterioles by A1 
receptor activation13,14. Both of these mechanisms are in place to stabilise 
GFR and prevent injury to the glomerulus by increased load. In healthy 
humans, as long as mean arterial blood pressure (MABP) is within a normal 
range (70-130 mmHg), RBF is able to autoregulate and remain stable even 
with changes in BP (Figure 1.2). In certain disease states however, including 
diabetes, salt-sensitive hypertension and CKD, we see impaired 
autoregulation11 while patients with essential hypertension retain their ability 
to autoregulate. Impaired renal autoregulation increases the susceptibility to 
glomerulosclerosis and proteinuria leading to renal disease even with modest 
changes in MABP, although the mechanisms behind alterations in 
autoregulatory sensitivity is still not understood. Although perfusion of the renal 
artery and kidney cortex are effective in their ability to autoregulate, the 
vasculature of the deep medulla is poorly autoregulated15, therefore the 
regulation of salt balance, fluid volume and blood pressure is determined by 
the renal artery and cortical vasculature16.  
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Figure 1.2 Autoregulation of renal blood flow in health and disease  
In healthy individuals, renal blood flow is maintained over a range of arterial pressures 
from around 70 to 130 mmHg by autoregulatory mechanisms. In humans with mild to 
moderate hypertension, the autoregulatory range is shifted to higher pressures due to 
elevations in preglomerular vascular tone and structural changes in the 
microcirculation. This is also seen in rodent models of hypertension such as SH or 
angiotensin II infused animals. In diabetic individuals, renal vascular resistance is 
reduced due to impaired efficiency of autoregulation. Figure adapted from Burke et 
al.17 
 
Autoregulation of perfusion is an intrinsic properly of both arteries and 
arterioles, in particular in tissues with protected circulations, including the 
heart, brain and kidneys. This tight regulation can, however, be modulated by 
extrinsic factors including nerves, hormones and vasoactive peptides18. 
Particularly potent in altering renal perfusion are endothelin-1 (ET-1) and ATP 
ET-1 causes a prolonged vasoconstriction of both the afferent and efferent 
arterioles and associated reduction in RBF and GFR19. When in the renal 
extracellular space, ATP can act in a paracrine manner by activating the P2 
family of receptors to cause vasoconstriction of juxtaglomerular afferent 
arterioles causing decreased renal perfusion20. More recently, complex Krebs 
cycle intermediates have been implicated in renal haemodynamics and the 
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control of blood pressure. For example, succinate, formed from fumarate, has 
been shown to activate GPR91 on the macula densa cells of the kidney to 
release prostaglandin E(2), a potent vasodilator and paracrine mediator of 
renin release, ultimately resulting in Ang II production, vasoconstriction of 
peripheral arteries, and an increase in blood pressure21. GPR91 activation has 
also been shown to cause initial vasodilation by prostaglandin E(2) of the 
afferent arterioles to control glomerular hyperfiltration22. Both of these findings 
present renal vasoactive mechanisms of GPR91 activation. My thesis 
focusses on the regulation of renal haemodynamics by GPR81, introduced 
below.  
 
1.3 HCA receptor family  
G protein coupled receptors (GPCR’s) are one of the largest protein families 
within mammals23. The hydroxy-carboxylic acid (HCA) subfamily of GPRC’s 
has 3 members, HCA1, HCA2 and HCA3 which are also referred to as GPR81, 
GPR109A and GPR109B, respectively. These receptors all have a single exon 
and high sequence homology with GPR81 being the most different; 
GPR109A/B share 96% sequence homology at a protein level while GPR81 
shares 55% of the amino acid sequence identity with the other two 
members24,25. It is therefore unsurprising that these receptors have been found 
to have similar endogenous ligands which are all intermediates of metabolic 
pathways. Nicotinic acid (Figure 1.3(D)) was first found to activate GPR109A26 
however endogenous plasma concentrations were shown to be too low for 
physiological receptor activation which lead to the discovery that the free fatty 
acid derived ketone body 3-hydroxybutyric acid (Figure 1.3(B)) could 
physiologically activate GPR109A but not GPR109B or GPR8127. Other 
endogenous carboxylic acids are also able to activate the receptor, but these 
have much lower plasma concentrations and are therefore not physiologically 
as relevant. Although GPR109A and B have only 16 amino acids difference in 
their sequence, these differences are essential for ligand binding and agonists 
of GPR109A do not activate GPR109B. In contrast, this receptor is activated 
by intermediates of mitochondrial β-oxidation of fatty acids, specifically 2- and 
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3-hydroxyoctanoic acid28. While plasma levels of 3-hydroxyoctanoic acid 
(Figure 1.3(C)) are increased sufficiently to activate the receptor in conditions 
which increase β-oxidation29 (e.g. starvation or ketogenic diet), currently the 
physiological relevance of 2-hydroxyoctanoic acid is unknown. Finally, GPR81 
is activated by its endogenous ligand lactate30,31 (Figure 1.3(A)). It has also 
been shown that other hydroxy-carboxylic acids, for example 2-hydroxy and 4-
hydroxybutyrate have some activity toward GPR81 however these have much 
reduced potencies in comparison to lactate and the physiological 
concentrations of these are much too low to be physiologically relevant30. 
Although single nucleotide polymorphisms have been identified in the HCA 
receptors, they have so far not been associated with any disease states and 
their physiological or pharmacological relevance are unknown32,33. 
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Figure 1.3 Agonists of the hydroxy-carboxylic acid receptors 
Hydroxy-carboxylic acid (HCA) receptors are activated by metabolic intermediates. (A) 
Lactic acid is the endogenous ligand for GPR81, (B) GPR109A is primarily activated 
by the ketone body 3-hydoxybutyric acid formed from fatty acids, (C) GPR109B is 
activated with the highest potency by 3-hydroxybutyric acid. (D) Nicotinic acid is able 
to exogenously activate GPR109A however plasma levels are too low. (E) 
AstraZeneca compound AZ’5538 was designed as a therapeutic compound which 
activates GPR81. Structures created using Chemspider, Royal Society of Chemistry.  
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Both GPR81 and GPR109A are found in most mammalian species, including 
humans and rodents, however GPR109B is limited to humans and higher 
primates28. The majority of expression of the three receptors in this subfamily 
is found within adipose tissue, both brown and white30,34,35 although they are 
seen throughout many tissue depots throughout the body at much lower levels. 
All three of the receptors have been shown to be expressed on a number of 
immune cells including macrophages, monocytes and neutrophils28,36–39. It has 
been suggested that both GPR109A/B are expressed in colonic epithelium as 
well as the skin40,41 although the function here is unclear. GPR81 has been 
shown to be expressed in the cardiovascular system including the heart and 
kidney30 as well as within certain regions of the brain with expression in both 
rodents and man being very similar 42,43. 
 
The HCA receptors are all Gi coupled receptors and activation by their 
respective ligands in adipocytes causes a reduction in cAMP which then acts 
to inhibit lipolysis. The mechanism of action of GPR81 is shown in Figure 1.4 
where lactate is produced from pyruvate via anaerobic glycolysis and released 
from the cell where it can bind to GPR81, activating the receptor. This inhibits 
adenylyl cyclase to lower levels of intracellular cAMP which downstream 
prevents the breakdown of triglycerides. Each ligand for the HCA receptors is 
released in response to different states and will inhibit lipolysis for different 
reasons. Arterial lactate is increased in states of hypoxia or intense exercise 
to prevent lipolysis in fat, and therefore lower FFA’s. This feedback drives 
energy production towards pyruvate as this has a lower oxygen requirement 
per mole of ATP produced44,45. Both GPR109A/B have ketone body ligands 
which reach a sufficient concentration to activate their receptors during states 
of increased β-oxidation, be this fasting, a ketogenic diet or diabetic 
ketoacidosis. These molecules are formed in the liver as a by-product of β-
oxidation of fatty acids. As the rate of lipolysis determines the amount of fatty 
acids available for β-oxidation, activation of GPR109A/B provides negative 
feedback for this system27,29,46. As GPR109B is only present in humans and 
higher primates, it is likely that these species require finer tuning for their 
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energy stores in adipocytes and have evolved to have another mechanism in 
place32.  
 
As previously stated, these receptors are also expressed on immune cells. 
Although the physiological role of GPR109A/B here is currently not 
understood, activation on these cells in vitro has been shown to increase levels 
of intracellular calcium28,37,47. On the other hand, a little more is understood 
about GPR81 and the immune system. Activation of GPR81 on mouse 
macrophages and human monocytes, suppresses Toll-Like Receptor 
pathways, preventing NLRP3 inflammasome activation and cell death39,48.  
 
 
Figure 1.4 Schematic diagram of the anti-lipolytic effects of GPR81 activation in 
adipocytes 
Lactate is formed intracellularly from glucose through glycolysis and is released. After 
binding to GPR81, the Gi signalling cascade inhibits adenylyl cyclase and halts ATP 
conversation to cAMP. A reduction in intracellular cAMP prevents the conformational 
change on protein kinase A needed to allow phosphorylation of hormone sensitive 
lipase and perilipin. These factors are therefore unable to hydrolyse triglycerides (TG) 
to free fatty acid (FFA) and glycerol. Figure based on Liu et al.l30 created using Servier 
Medical Art, Les Laboratoires Servier. 
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 HCA receptors as a therapeutic target 
Due to the anti-lipolytic effects of HCA receptor activation, it is unsurprising 
that the majority of the therapeutic drugs designed for these receptors are for 
the treatment of dyslipidemias. These aim to prevent the breakdown of lipids 
into FFA’s via lipolysis inhibition, which drives glycolysis rather than β-
oxidation, lowering blood glucose49. An excess of FFA release is also known 
to amplify insulin resistance50 and therefore inhibition of lipolysis improves the 
insulin sensitivity in obese or diabetic patients. Furthermore, reducing the pool 
of FFA reduces the ability for the liver to produce low density lipoprotein (LDL) 
from very low density lipoprotein (VLDL)51, thus improving the lipid profile. 
Before the identification of the endogenous agonists of GPR109A, nicotinic 
acid was discovered to activate the receptor which has been historically used 
as an anti-dyslipidemic drug52. Niacin also activates GPR109B in humans but 
at a lower affinity (EC50 values of 0.1 µM and 100 µM, for GPR109A and B, 
respectively)53. It has also been shown that niacin offers anti-atherosclerotic 
benefits, in particular when used in combination with statins54. Clinical trials 
have shown that this combination therapy not only lowers plasma LDL and 
raises HDL but also promotes cholesterol efflux in atherosclerotic plagues54–
56. The major side effect of niacin as a drug is that it causes cutaneous flushing 
which severely impacts patient compliance of the drug. This is due to the 
expression of GPR109A on dermal Langerhans cells of the skin where 
activation causes the formation of prostanoids57,58. Synthetic ligands for 
GPR109A (both partial and full agonists) have been designed with some 
success59,60. The aim of these drugs are to reduce the flushing response of 
niacin, as this is not a Gi mediated effect61, while preserving the beneficial anti-
lipolytic effects. Although there are agonists designed to specifically activate 
GPR109B62,63 they are not believed to have benefits over niacin due to the 
similarity in expression patterns between the two receptors. Research into 
these specific agonists is particularly difficult due to the lack of expression of 
the receptor in rodents without a transgenic mouse model to express 
GPR109B. Conversely, GPR81 has quite a different expression pattern than 
the other two HCA receptors, in particular, GPR81 is not expressed in 
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Langerhans cells and therefore activation of the receptor does not cause 
flushing64. This receptor has therefore recently become the target of many drug 
companies to produce specific GPR81 agonists to treat dyslipidemias and 
prevent cardiovascular risk without the adverse effects of GPR109A/B 
agonists64–66.  
 
Aside from treatment of dyslipidemias, GPR109A has been considered as an 
anti-inflammatory target, in particular in the treatment of psoriasis. 
Monomethylfumarate, an established anti-psoriatic, has been shown to 
activate GPR109A on immune cells but not GPR109B or GPR8167, however 
this compound also causes side effects similar to niacin including flushing68. 
The anti-inflammatory effects of GRP109A activation also help to explain the 
anti-atherosclerotic effects of niacin which have been reported to be due to the 
receptors expression on macrophages in atherosclerotic plaques56. GPR81 is 
also expressed in immune cells where it has been shown to have positive anti-
inflammatory effects in the liver and digestive system. Activation of GPR81 by 
the endogenous ligand lactate in vivo reduces inflammation and organ injury 
in a model of immune hepatitis in a Gpr81-dependant manner and was also 
shown to reduce the severity of acute pancreatitis and liver injury in mice39. In 
an experimental mouse model of colitis, GPR81 activation on immune cells 
with pharmacological agents decreased inflammatory cytokine expression and 
ameliorated colonic inflammation48. 
 
Experimental models of brain disease and injury have also been used to look 
at HCA receptor activation and their potential beneficial role here. GPR109A 
has been shown to be expressed on neuroinflammatory cells in the brain 
where activation reduces inflammation in mouse models of multiple sclerosis 
or stroke69. The role of GPR81 in the brain injury is controversial with studies 
reporting both positive and negative effects of GPR81 activation. It has been 
reported that GPR81 expression is upregulated in the brain in rodent models 
of stroke or cerebral ischemia and activation of the receptor by increased 
lactate may aggravate the injury70–72. Overexpression of GPR81 in vitro 
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increased cell vulnerability to ischemic injury and therefore antagonism of 
GPR81 was postulated as a therapeutic strategy for ischemic brain injury72. 
Inhibition of GPR81 with 3-hydroxy-butyrate prevented cell death and brain 
injury in both an in vitro model of oxygen-glucose deprivation as well as an in 
vivo mouse model of middle cerebral artery occlusion72. In stark contrast, 
activation of the receptor by 3,5-dihydrobenzoic acid was shown to prevent cell 
death by apoptosis and offer neuroprotection in the same models of both in 
vivo and in vitro brain ischemia70. 
 
Finally, the HCA receptors have also been implicated in certain types of 
cancer. The expression of GPR109A/B in the gastrointestinal (GI) tract has 
been investigated for its therapeutic target here. In colon cancer, the receptor 
is silenced and re-expression and activation of the receptor by its ligands 
causes tumour cell apoptosis40. GPR81 expression has been reported in 
multiple cancer cell lines including colon, lung, salivary gland, cervical and 
pancreatic where expression levels correlated with the rate of pancreatic 
cancer tumour growth and metastasis73. In breast cancer patients and cell 
lines, GPR81 expression has been found to be significantly higher in than that 
of normal cells or mammary tissue74. In this study, GPR81 knockdown using 
shRNA resulted in impaired breast cancer growth, supressed angiogenesis 
and increased apoptosis showing that knockdown of the receptor retards the 
development/metastasis of breast cancer.  
 
 Lactate and disease 
Lactate is produced in the majority of tissues within the human body, with the 
highest levels of production in muscle75. An overview of lactate production and 
metabolism is shown in Figure 1.5. In humans, the main sources of lactate are 
glucose and alanine through their conversion into pyruvate76. Lactate is 
produced when oxygen stores are low, in anaerobic conditions. In aerobic 
conditions, pyruvate is produced from glucose via glycolysis and then enters 
the tricarboxylic acid (TCA) cycle, bypassing lactate production. However, 
under anaerobic conditions, lactate is the end product of glycolysis, requiring 
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no oxygen. Lactate and pyruvate are either produced or removed by the 
enzyme lactate dehydrogenase which is principally in the cytosol of the cell. 
This reaction includes the oxidation of NADH to NAD+ in the 
thermodynamically favoured direction of pyruvate reduction to lactate or vice 
versa77.  
 
Lactate clearance, in healthy individuals, is carried out rapidly by the liver with 
additional clearance in the kidney78. The first step of clearance is the oxidation 
of lactate to pyruvate in the cytosol which is transported to the mitochondrial 
network by the mitochondrial pyruvate carrier (MPC) proteins79. Pyruvate can 
then generate endogenous glucose via oxaloacetate or can undergo oxidative 
metabolism via the generation of acetyl-CoA. Deterioration of either of these 
pathways can result in lactate accumulation.  
 
In general, lactate elevation may be caused by increased production, 
decreased clearance, or a combination of the two80. As lactate is produced 
under anaerobic conditions, tissue hypoperfusion or hypoxia are the most 
common causes of elevated lactate production81. However, there are a 
multitude of causes for elevated plasma lactate in patients. These include 
shock, regional tissue ischemia, diabetes, drugs, toxins and pharmacological 
agents80. Liver dysfunction is also a key cause as this may contribute to both 
increased production and deceased clearance. There is a wealth of literature 
on lactate increases with excessive muscle activity and heavy exercise due to 
anaerobic metabolism82. Hyperlactatemia has also been associated with 
mortality in hospitals. A study from the Netherlands showed that plasma lactate 
levels >4 mmol/L at admission to the emergency department showed a 
scientifically higher risk of mortality than patients with lower levels of lactate83. 
While another study showed plasma lactate of even >2.6 mmol/L is a predictor 
of mortality within 30 days of hospital admission84. This shows the clinical 
significance of measuring plasma lactate and importance of lactate in disease. 
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Figure 1.5 Schematic diagram of lactate metabolism 
Lactate is formed from pyruvate by lactate dehydrogenase or vice versa. The majority 
of pyruvate is formed from either glucose or alanine in the cytosol. Lactate is 
metabolised by conversion to pyruvate which can either enter gluconeogenesis to 
produce glucose via oxaloacetate or enter the tricarboxylic acid (TCA) cycle to produce 
ATP via acetyl-coA. 
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 GPR81 and vascular function  
A role for GPR81 and its endogenous ligand lactate in the cardiovascular 
system has been suggested, specifically within the vasculature. Lactate is able 
to activate GPR81 with an EC50 of ~5 mM31 while under normal physiological 
conditions, plasma lactate has a concentration of 0.5-2 mM, rising to 10-30 
mM during intense exercise or prolonged hypoxia30,31,85. Although tissue levels 
of lactate are very rarely measured, in mice at baseline lactate in brown fat is 
~2 mM86 while after treadmill exercise muscle lactate is ~4 mM87. Tissue 
lactate is known to rise substantially under states of ischemia80 which suggests 
that the receptor is either physiologically quiescent under basal conditions or 
that it is responsive to the local, rather than circulating, concentration of lactate 
in particular in states of ischemia88. Prior to the discovery that lactate was the 
endogenous ligand of GPR81, there were also reports that this compound was 
able to exhibit vasomotive effects. For example, it was historically reported that 
intravenous (IV) infusions of lactate in anaesthetised Spontaneously 
Hypertensive (SH) and Wistar rats causes a rapid and short lived increase in 
blood pressure compared to a saline control89. In this study, a non-
physiological or pathophysiological concentration of lactate was used (0.5 M) 
with the aim of inducing panic in the mice which would have had multiple off 
target effects, including blood pH changes, which is an obvious caveat to this 
study. In contrast, lactate treatment ex vivo has been shown to cause direct 
vasodilatory effects. On preconstricted rat mesenteric resistance arteries, 
addition of lactate from 6 mM to 50 mM caused vasorelaxation which was 
shown to not be dependent on pH, the presence of the endothelium or nitric 
oxide90. In the same way, treatment of lactate on contracted isolated porcine 
retina caused significant increases in capillary blood vessel diameter 
suggesting dilation of these vessels91. Conversely, the retinal 
microvasculature from mice responded from basal tension to lactate by 
constricting and decreasing the luminal diameter92. In this study, hypoxia 
altered the effect of lactate to vasorelaxation and it was suggested that lactate 
may serve to constrict blood vessels when energy supplies are ample but in 
response to local metabolic need can switch to vasodilation once stores are 
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restricted. These effects were not confirmed to be GPR81 mediated, with the 
authors suggesting the findings were caused inhibition of Na+/Ca2+ 
exchangers. 
 
As previously discussed, a role for GPR81 in breast cancer has been studied. 
Although a negative effect in this disease state, the study showed that GPR81 
is involved in angiogenesis and promotes the release of pro-angiogenic 
factors74. In the same way, both treadmill exercise (to increase plasma lactate 
concentration) as well as subcutaneous injections of lactate increased the 
expression of vascular endothelial growth factor A (VEGFA) and capillary 
density in the brain42. This finding was GPR81 specific with Gpr81 null mice 
showing no difference to vehicle controls. In the support of a vasoactive role 
of GPR81, expression has been shown by a RFP reporter mouse line to be 
enriched in the pial fibroblast-like cells which line the vessels of the brain42 as 
well as the smooth muscle cells of the mouse brain by single-cell RNA 
sequencing93,93. Using the GPR81-RFP reporter mouse alongside an 
endothelial cell marker, CD31, it was shown that expression did not co-
localise42. There is currently a lack of data on the expression of GPR81 within 
the vasculature throughout the rest of body or at distinct localisation in the 
kidney.  
   
The most recent study on the cardiovascular involvement of GPR81 was 
carried out by collaborators at AstraZeneca (Gothenburg, Sweden). They 
designed a specific agonist for GPR81, AZ13415538 (referred to in the study 
as AZ2 and for the rest of this thesis as AZ’5538), for the potential therapeutic 
use in metabolic disorders involving dyslipidaemias, in particular type II 
diabetes. This agonist activates GPR81 with an in vivo potency for GPR109A 
40 and 7 times lower in humans and mice respectively. IV infusions of this 
agonist in dogs and rats found increases in blood pressure and decreased 
renal blood flow. In vivo rat studies with an infusion of the agonist over a 15 
minute period resulted in blood pressure increases (~15 mmHg) and renal 
blood flow decreases (20-30% of basal)65. This was coupled with increased 
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urine flow followed by a delayed increase of ion excretion. The rise in blood 
pressure was rapid, suggesting an alteration in total peripheral resistance 
rather than blood volume and salt changes which involve long term 
homeostatic mechanisms94. Due to these adverse effects, it is unlikely that 
GPR81 agonists will progress to clinical trials but can be used as tool 
compounds to study the receptor and its function. During my MSc in 
Cardiovascular Biology, these findings were confirmed in rats. This suggests 
that there is a mechanism by which GPR81 is involved in the regulation of 
blood pressure in vivo. In addition to these findings, the authors also reported 
that in rats, the pressor response of AZ’5538 could be prevented with IV 
treatment of the mixed endothelin receptor antagonist bosentan. This indicates 
a link between the mechanism of GPR81 induced blood pressure increase and 
the endothelin system.  
 
1.4 The endothelin system 
There are three peptides in the endothelin family which activate two Gq protein 
coupled endothelin receptors which cause vasoactive effects. Endothelin-1 
and endothelin-2 (ET-1 and ET-2) differ by only 2 amino acids in most 
mammals and activate both the endothelin A receptor (ETRA) and endothelin 
B receptor (ETRB) with equal affinity while endothelin-3 (ET-3) has a much 
lower affinity to ETRA in comparison to the other isoforms95–97. ET-1 is the 
most abundant isoform in humans and for that reason the majority of the 
literature focuses on this peptide as it is most relevant in the cardiovascular 
system.  
 
ET-1 is synthesised continuously as pre-proendothelin (preproET-1) primarily 
by endothelial cells and has been located in all types of vessels. The peptide 
then undergoes a series of cleavage events to generate bigET-1 which is 
subsequently cleaved by endothelin converting enzymes (ECE) to produce 
mature ET-198,99. This vasoactive peptide is produced and secreted in 
mammals in a dual pathway which is shown in Figure 1.6. In the first, 
constitutive, pathway bigET-1, ET-1 and ECE-1 are continuously released 
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from small secretory vesicles100. Much like lactate and GPR81, levels of ET-1 
in plasma tend to be too low to activate ETRA and it is therefore believed to 
be a local paracrine mediator or blood pressure. However, endogenous 
continuous production of ET-1 by ECE from bigET-1 through the constitutive 
pathway has been shown to be necessary for maintenance of basal vascular 
tone through activation of ETRA100. The control of preproET-1 gene 
expression, and therefore the constitutive pathway, are largely controlled at a 
transcriptional level101. 
 
The other mechanism of ET-1 release is the regulated pathway. BigET-1, ET-
1 and the ECE enzymes are stored in specialised Weibel-Palade storage 
granules which are unique to endothelial cells102. In the regulated pathway, an 
external stimulus (physiological or pathophysiological) causes the release of 
ET-1 from these bodies. Activation of the different receptors after release 
cause contrasting effects on vascular tone.  
 
Upon release, ET-1 can activate ETRA (or a small number of ETRB) on 
smooth muscle cells of the vascular medial layer to cause direct 
vasoconstriction by increasing intracellular calcium concentration103,104. The 
complex of receptor and ligand is then internalised to the endosome to be 
recycled back to the cell surface. ET-1 can also activate ETRB on endothelial 
cells to cause release of vasodilatory compounds, including nitric oxide and 
prostacyclin to cause vasodilation in an autocrine manner which limits the 
vasoconstrictor response of ET-1 and maintain cardiovascular homeostasis105. 
Expression of the two ET receptors differs between tissues with higher levels 
of ETRB in the brain and whole kidney106 while ETRA is enriched in the 
cardiovascular system and especially the vasculature of the kidney101. ET-1 is 
cleared rapidly from the circulation through the lungs, kidney and liver107,108, 
and ETRB is believed to be the main receptor responsible for this109. 
 
ET-1 is also produced by cell types other than vascular endothelial cells, 
including other epithelial cells types110, at lower levels. Vascular smooth 
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muscle cells (VSMC) are also able to produce ET-1 which can alter vascular 
responsiveness111,112. However the production in isolated aortae is 
significantly lower than in endothelial cells, making it less physiologically 
signficiant113. Immune cells including macrophages, dendritic cells and 
monocytes are able to produce ET-1, with the latter increasing ET-1 release in 
response to T-cell activation110,114,115. Finally, cardiomyocytes have been 
shown to express ET-1 where the peptide is involved in detrimental cell 
differentiation in hypoxia116 and contractile function117. 
 
Until the suggestions by Wallenius et al., a direct connection between lactate 
(or GPR81) and ET-1 had not been reported. However, it is known that both 
lactate and endothelin are significantly increased during states of hypoxia both 
in vitro and in vivo118–122. There are also similarities reported in the actions of 
GPR81 activation and ET-1 actions on ETRA including increased BP pressure 
and reduced RBF65,123–125. Based on these findings, and the lack of GPR81 
responses with endothelin receptor blockade, an unknown link between these 
two systems could be hypothesised. 
 
Compounds to antagonise the endothelin receptors have been in use for many 
years both as tool compounds to study the endothelin system as well as a 
treatment for cardiovascular disorders. Anti-endothelin agents have been 
trialled for hypertension, CKD, heart failure and atherosclerosis to name a 
few126. The mixed antagonist Bosentan which targets both receptors was the 
first endothelin receptor antagonist to make it into the clinic for PAH127. While 
BQ-123 and BQ-788 have historically been used to study ETRA and ETRB, 
respectively128,129.  
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Figure 1.6 Endothelin-1 release and mechanisms of action 
Endothelin-1 (ET-1) is first synthesised as big ET-1 in endothelial cells which is cleaved 
by endothelin converting enzyme (ECE) to form mature ET-1. The peptide is 
continuously released in the constitutive pathway where small vesicles release ET-1 
from the cell to maintain normal vascular tone. ET-1 is also released by the regulated 
pathway in response to physiological or pathophysiological external stimuli. This 
releases ET-1 from Weibel-Palade bodies which are endothelial specific. Once 
released, the majority of ET-1 interaction is with endothelin A receptors (ETRA) on 
smooth muscle cells to cause vasoconstriction. A small population of endothelin B 
receptors (ETRB) are present on some smooth muscle cells and are able to mediate 
vasoconstriction. The ET-1/ETRA complex undergoes internalisation to the endosome 
and is recycled back to the cell surface. ET-1 is also able to interact with ETRB in an 
autocrine manner on endothelial cells to produce vasodilators such as nitric oxide to 
limit the constrictor response. Figure adapted from Maguire et al.101 and created using 
Servier Medical Art, Les Laboratoires Servier101. 
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1.5 Hypothesis and aims  
The overarching hypothesis of my thesis is that: 
 
GPR81 is a novel regulator of vasomotive tone and influences blood pressure 
in an endothelin-1-dependent manner. 
 
To address this hypothesis, I aim to localise the expression of GPR81 in the 
kidney as well as within the vasculature of the mouse, to determine cardiorenal 
effects of GPR81 activation and utilise the Gpr81 null mouse to assess the 
specificity of these actions. Secondly, I aim to identify and dissect the potential 
interaction between the GPR81 and endothelin systems. Finally, I will employ 
wire myography to evaluate the potential direct vasoactive role of GPR81.  
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Chapter 2 - Materials and 
Methods 
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2.1 Animal husbandry  
Procedures were performed under the 1986 UK Home Office Animals 
(Scientific Procedures) Act, following ethical review by the University of 
Edinburgh. Experiments were performed on male C57BL/6JCrl (Charles River, 
Paris, France) or Gpr81 wildtype or knockout mice65 aged 10-12 weeks. Mice 
had with free access to standard chow and water and were housed at 22°C ± 
1°C, 55% humidity and on a 12 hour light dark cycle (lights on at 07:00). 
 
2.2 Expression of Gpr81 
 Tissue harvesting 
Adult male C57BL/6JCrl mice were culled via asphyxiation with CO2 prior to 
dissection. Aortae, whole decapsulated kidneys connected to the abdominal 
aorta with renal arteries and veins intact, and whole mesenteries were 
removed in ice cold physiological salt solution (PSS; 119.0 mM NaCl, 3.7 mM 
KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 25.0 mM NaHCO3, 1.2 mM KH2PO4, 27.0 
μM EDTA, and 5.5 mM D-glucose). Renal arteries were dissected from the 
kidneys and mesenteric arteries isolated. Renal and mesenteric arteries were 
pooled from 2 mice. Kidneys were placed immediately on dry ice and stored 
at -80oC prior to RNA extraction. Vessels were stored in 1 mL RNAlater 
(Thermo Fisher, Paisley, UK) at 4oC for 24 hours before removal from the 
solution and storing at -80oC. 
 
 Extraction of RNA and conversion to cDNA 
On dry ice, vessels were ground into a fine powder using a pestle (Thermo 
Fisher) before homogenisation and a modified protocol for the RNA extraction 
using the RNeasy Micro kit (Qiagen, Hilden, Germany) was carried out. 300 
µL of RLT buffer (from the RNeasy kit) was added to the crushed vessels along 
with a 5 mm stainless steel homogenisation bead (Qiagen). Samples were 
homogenised in a TissueLyserII (Qiagen) at 30 Hz for 1 minute. Proteinase K 
(Thermo Fisher, diluted 1:60) was added to samples prior to incubation at 55oC 
for 10 minutes. Samples were then centrifuged for 3 minutes at 10,000 rpm, 
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mixed with 350 µL 70% ethanol (Sigma Aldrich, St. Louis, MO, US) and 
transferred to a Micro-Elute spin column. The spin steps were then carried out 
according to manufacturer’s protocol and RNA eluted in 14 µL RNase free 
water (Thermo Fisher). 
 
RNA concentration and quality of all samples was assessed by a Nanodrop 
1000 spectrophotometer (Thermo Fisher). cDNA was then synthesised 
following the High Capacity cDNA Reverse Transcription kit protocol (Applied 
Biosystems, CA, USA). 300 ng of vessel RNA was included in the reaction mix 
along with 10 µL of 2x RT buffer, 1 µL of 20x enzyme mix and made up to 20 
µL with nuclease free water. Internal controls excluding the reverse 
transcriptase enzyme or RNA were run alongside. Samples were run in a Veriti 
thermocycler (Applied Biosystems) for 60 minutes at 37oC followed by 5 
minutes at 95oC before storage of cDNA at -20oC. 
 
 End point PCR for Gpr81 expression 
Primers for end point PCR for Gpr81 were designed using NCBI Primer-Blast 
(Table 2.1). RNA samples from aortae, mesenteric arteries and renal arteries 
were diluted 1:5 in nuclease free water prior to PCR. Each reaction contained 
10 µL VWR Red Taq DNA Polymerase 2x Master Mix (VWR, Lutterworth, UK), 
0.4 µL of each 10 pmol/µL primer (IDT, IA, USA), 8.2 µL of nuclease free water 
and 1 µL cDNA. PCR was run in a Veriti thermocycler with the following 
conditions; initial activation 94°C for 5 minutes, 35 cycles of denaturation (30 
seconds at 94°C), annealing (60 seconds at 56°C) and extension (60 seconds 
at 72°C) and final extension of 7 minutes at 72°C. 
 
 
Table 2.1 End point PCR primers for Gpr81 
Designed using NCBI Primer-Blast 
 
Gene name Protein Forward Primer Reverse Primer Product size
Hcar1 GPR81 ttggagatatcgcctgtcgc ggctccaaacaacgttgacc 360bp
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12 µL of PCR product were run 12 µL of each sample run on a 2% agarose 
gel with ethidium bromide (1:10,000) at 80 v (300 mA) for 1 hour 30 mins 
before imaging. 
 
 qPCR for Gpr81 expression 
Quantitative polymerase chain reaction (qPCR) was performed in triplicate 
with the Roche Universal Probe Library (UPL) system using a Lightcycler 480 
(Roche, West Sussex, UK). For each gene, a 7 point standard curve (1:10-
1:640) was carried out containing a mix of all samples to be analysed to which 
each sample was normalised. Kidney and artery samples were diluted 1:20 
prior to qPCR. Primers for GPR81, 18S and β-actin (Table 2.2) were designed 
with the UPL Assay Design Centre and used at a final concentration of 250 nM 
with UPL probes and PerfeCTa FastMix II (Quanta bio, Beverly, MA, USA). 
Gene expression was analysed as relative expression once normalised to the 
mean expression of the two housekeeping genes, 18S and β-actin.  
 
 
Table 2.2 Primers and UPL probes used for Gpr81 qPCR 
Primers designed using UPL Assay Design Centre. 
 
 Genotyping of Gpr81-/- mice 
The global Gpr81-/- mouse line was created by AstraZeneca (Gothenburg, 
Sweden). Briefly, a conditional KO strategy was used for gene deletion, 
flanking Gpr81 exon 1 with LoxP sites. A targeting vector containing a frt-
flanked neo-selectable marker cassette was utilised, and the targeting 
construct was electroporated into a C57BL/6JOlaHsd-derived embryonic stem 
cell line. After homologous recombination, clones were injected into 
blastocysts to generate chimeric males that were then bred, and black-coated 
offspring were genotyped for correct integration into the Gpr81 locus. The neo-
Coding 
protein
Gene 
Name Forward Primer Reverse Primer
UPL probe 
number 
18S Rn18s gccgctagaggtgaaattctt cgtcttcgaacctccgact 93
β-Actin Actb ctaaggccaaccgtgaaaag accagaggcatacagggaca 64
GPR81 Hcar1 ggtggcacgatgtcatgtt gaccgagcagaacaagatgatt 4
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selectable marker cassette was deleted after subsequent breeding to mice 
expressing flp recombinase under the CAG promoter. Gpr81 exon 1 was 
deleted after subsequent breeding to mice expressing Cre recombinase. Mice 
were then bred onto a C57BL/6NCrl background65. 
 
For the genotyping of offspring, genomic DNA was extracted from ear punch 
biopsies from weened pups using the ‘HotSHOT’ protocol130. Tissue was 
incubated with 75 µL of alkaline lysis reagent (25 mM NaOH, 0.2 mM EDTA in 
ddH2O, pH 12) at 95oC for 30 minutes before cooling to 4oC on ice. Then, 75 
µL of neutralisation buffer was then added (40 mM Tris-HCl in ddH2O, pH 5). 
DNA could then be stored at -20oC.  
 
PCR was carried out using the Qiagen Multiplex PCR plus kit (Qiagen) with 
the following components: 2 µL genomic DNA, 12.5 µL 2x Master mix, 0.2 µM 
of each primer, 2.5 µL 5x Q solution and made up to 25 µL with RNase free 
water. Primer sequences for the genotyping are shown in Table 2.3. Samples 
were then run in a Veriti thermocycler for 5 minutes at 95oC, 35 cycles of 95oC 
for 30 seconds, 63oC for 30 seconds and 72oC for 90 seconds and a final step 
of 68oC for 10 minutes.  
 
Each sample had 2 µL of 6x DNA gel loading dye (Thermo Fisher) added 
before being run alongside a 100 bp DNA ladder (New England Biolabs, MA, 
USA) on a 2% agarose gel with 1:10,000 gel red (Scientific Laboratory 
Supplies, Newhouse, UK) at 100 V (300 mA) for 40 minutes. A product of 469 
bp indicates a Gpr81 null mouse, 254 bp indicates a wildtype while both show 
a heterozygote mouse. An example of a genotyping gel is shown in Figure 2.1. 
 
 
 28 
 
Table 2.3 Genotyping primers for Gpr81 mouse colony 
Primers sequences provided by AstraZeneca (Gothenburg, Sweden). 
 
 
 
Figure 2.1 Representative genotyping gel the Gpr81 mouse line 
DNA samples extracted from ear clips from the Gpr81 mouse line underwent PCR 
before running on an agarose gel. A Gpr81+/+ (WT), Gpr81-/- (KO) and Gpr81+/- (HET) 
shown here. 
 
 In situ hybridisation using RNAscope  
RNAscope 2.5 HD red assay (ACD, Abingdon, UK) was carried out using 
manufacturer assay instructions131 with some optimisation steps and are 
briefly explained below. 
 
2.2.6.1 Sample preparation and pre-treatment 
Gpr81-/- mice and WT littermates were culled via asphyxiation with CO2 before 
the dissection of kidneys, renal arteries and aorta. One kidney was cut in a 
longitudinal manner while the other was cut transverse. All samples were 
stored in 10% neutral buffered formalin (Sigma) for 24 hours at room 
Primer 1 Primer 2 Primer 3
aatgtaagcagttggcctgg agaggcaggtggatctctga cacaaaggagtcaaaagccc
WT band (p2-p3) KO band (p1-p2)
254bp 469bp
WT KO HET
500bp
200bp
300bp
254bp
469bp
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temperature before being transferred to 70% ethanol (Sigma). Samples were 
dehydrated using an ethanol series followed by xylene. Samples were then 
embedded into paraffin blocks. Sections of 5 µm were mounted onto 
Superfrost Plus slides (Thermo Fisher) and airdried at room temperature.  
 
Slides were baked at 60oC in a dry oven for 2 hours before deparaffinising 
using 100% xylene then ethanol (both Sigma). Slides were baked at 60oC for 
30 minutes before sections were covered in hydrogen peroxide (ACD) and 
incubated at room temperature for 10 minutes. All slides were then washed in 
distilled water. For manual target retrieval, slides were submerged into boiling 
RNAscope 1X Target Retrieval Reagents solution for 15 minutes for kidney 
and both vessel types and then washed with 100% ethanol. Slides were again 
baked at 60oC for 30 minutes. A barrier was then drawn around the tissue 
using Immedge hydrophobic barrier pen (Vector, Peterborough, UK) and left 
to dry overnight. Slides were then covered with RNAscope Protease Plus 
solution and incubated in a HybEZ oven (ACD) at 40oC for 30 minutes and 
washed in distilled water. 
 
2.2.6.2 RNAscope 2.5 HD red assay  
To begin the assay, slides were covered with the appropriate mouse specific 
probe (Gpr81, positive control Ppib or negative control DapB) and incubated 
for 2 hours in the HybEZ oven at 40oC. Slides were not allowed to dry out as 
they were hybridised with AMP1-6 and washed in RNAscope wash buffer in 
between. Signal was then detected by covering the slides with a 1:60 ratio of 
RNAscope Fast RED-B to Fast RED-A and incubated in the dark for 10 
minutes at room temperature. Slides were then counterstained in 50% Gills 1 
haematoxylin (Sigma) for 2 minutes before being submerged into 0.02% 
Ammonia water (Sigma). Slides were dried at 60oC before mounting coverslips 
using EcoMount (Biocare, CA, USA).  
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2.2.6.3 Image acquisition 
Slides were imaged using an Axio Scan SlideScanner (Ziess, Cambridge, UK). 
Images were then processed using QuPath132 and Image J software133 (Fiji). 
Success of the assay was judged by strong positive signal of PPIB 
(Peptidylprolyl Isomerase B) and no signal in dapB samples (an E.coli specific 
gene). 
 
2.3 In vivo analysis of GPR81 activation 
 Terminal cannulation of vessels 
The following protocol was carried out for all subsequent in vivo studies. Mice 
were anaesthetised with an interpretational (IP) injection of Inactin (sodium 
thiobutabarbital, Sigma, 120 mg/kg). Additional doses of anaesthesia were 
administered as required by monitoring toe pinch and blink reflexes. Lidocaine-
HCl (2% w/w in 0.9% saline, Sigma) was injected to provide local anaesthetic 
at incision sites. Core body temperature was maintained at 37oC using a servo-
controlled heat plate (AD Instruments, Oxford, UK). 
 
A ventral cervical skin incision was made and the muscles immediately 
beneath were dissected to expose the left jugular vein. Perivascular fat was 
gently removed with fine forceps, the anterior end ligated (size 5 suture silk, 
Fine Science Tools, CA, USA) and the vessel cannulated with 15 cm of P10 
tubing (Smiths Medical, Kent, UK) attached to a 1mL syringe containing 0.9% 
saline. For studies requiring infusion of two substances at once, two 15cm 
sections of P10 tubing were inserted into the left jugular vein, for example in 
the renal clearance experiments. Cannulas were then tied in with a second 
ligature.  
 
Next, the trachea was opened to maintain a clear airway. The muscles around 
the trachea were dissected to expose it and a small piece of P50 tubing 
(Smiths Medical) was inserted directly under the trachea to raise it slightly. An 
incision was made between tracheal cartilage rings and fluid build-up was 
cleared using small twists of tissue throughout experiments. 
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The carotid artery was cannulated for blood pressure and heart rate recording 
and for arterial blood collection. The artery was separated from the vagus 
nerve before anterior ligation. The posterior end was ligated with a vessel 
clamp to prevent blood loss. A small incision in the vessel was made where a 
length of P50 tubing with 1cm of P10 tubing at the end was inserted and tied 
in place. This tubing was attached to a 1 mL syringe containing 20 units/L 
porcine heparin saline (Sigma). The clamp was then removed to restore blood 
flow. The carotid cannula was connected to a ML224 Bridge Amp for arterial 
blood pressure monitoring through LabChart data acquisition software (both 
AD Instruments). 
 
Finally, the bladder was catheterised for urine collection. A lower abdominal 
incision followed by one in the peritoneum was made so the bladder could be 
located and gently raised out. A hole was made in the bladder using a needle 
and a ~5 cm length of P50 tubing was inserted and tied in place.  
 
Animals were equilibrated post-surgery for 30 minutes before a 15 minute 
infusion of 5% D-mannitol vehicle (pH 5) followed by AZ’5538 (1 µmol/kg 
bw/min; pH 5). Unless otherwise state, all IV infusion rates were 0.2 mL/10g/Hr 
using an AL2000 infusion pump (World Precision Instruments, FL, USA). 
 
 Pulse-wave Doppler ultrasound 
Post-surgery, C57BL/6JCrl were mice placed in the supine position on a heat 
pad. Pulse-wave Doppler using a Vevo 770 with a 707B 30 MHz ultrasound 
probe (VisualSonics, Toronto, Canada) measured blood flow from the right 
renal artery. Peak velocity was measured at baseline and over 5 minute 
periods during IV administration of vehicle followed by AZ’5538 as above. 
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 Doppler flow probe and needle flux probe placement 
Doppler flow probe experiments were carried out in both C57BL/6JCrl mice 
and Gpr81-/- and wildtype littermates while needle flux probes were only used 
in the Gpr81-/- mouse line with wildtype controls. 
 
For both procedures, mice underwent an additional midline laparotomy after 
the cannulation of vessels. This allowed the placement of either a Doppler 
transit time probe (Transonic, Ithaca, NY, USA) around the right renal artery 
(Surgilube gel (HR Pharmaceuticals, Pennsylvania, USA) was used for 
acoustic coupling) or Doppler flux probes (Transonic) inserted into the cortex 
and medulla of the right kidney. Probe position was confirmed post-mortem. 
All data was acquired through LabChart software (AD Instruments). 
 
 Renal clearance measurements 
Renal clearance studies were carried out in both C57BL6/JCrl mice and the 
Gpr81 mouse line. All mice underwent surgery as previously discussed with 2 
IV lines in the right jugular vein. Mice were equilibrated post-surgery for 40 
minutes where they received infusate (100 mM NaCl, 5 mM KCl, 15 mM 
NaHCO3-, and 0.25% FITC- inulin (Sigma), pH altered to 7.4 by bubbling with 
CO2) at 0.2 mL/10g/Hr through one IV line) before the first urine collection 
period. The protocol was broken down into 3 collection periods where urine 
was collected into pre-weighed 500 μL Eppendorf tubes containing mineral oil 
to prevent sample evaporation and around 50 µL of blood was collected 
lithium-heparinised capillary tubes (Sarstedt, Nümbrecht, Germany) before 
and after the period which was spun for 5 minutes at 10,000 rpm to separate 
plasma. Firstly, over 40 minutes, mice continued to receive infusate along with 
5% D-mannitol vehicle through the second IV line at 0.1 mL/10g/Hr, increasing 
the infusion rate to 0.3 mL/10g/Hr total. The next period of 15 minutes mice 
either continued to receive vehicle or AZ’5538 (1 µmol/kg/min at 0.1 
mL/10g/Hr) along with infusate (in the studies in the Gpr81-/- mice and 
littermates, all mice received AZ’5538). For the final 40 minutes, mice 
continued with the same infusions. At the end of the experiment, terminal 
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plasma was collected in 500 µL lithium-heparinised tubes (Starstedt), mice 
were culled via cervical dislocation and kidneys weighed. 
 
To calculate FITC-inulin concentrations, plasma and urine samples were 
diluted 1:100 and 1:10,000 in HEPES buffer (Sigma, 10 mM, pH7.4), 
respectively. A 9 point standard curve (10-0.04 µg/mL) and blank HEPES only 
sample were run alongside. 190 µL of each sample and standard was loaded 
in duplication into a Microfluor black 96 well plate (Thermo Fisher). Plates were 
read using an Infinite M1000 microplate reader (Tecan, Männedorf, 
Switzerland) with an excitation of 485 nm and emission of 538 nm  
 
Glomerular filtration rate (GFR) was calculated from the FITC-inulin 
concentrations of plasma ([Pinulin]) and urine ([Uinulin]) samples determined from 
the standard curve. GFR was calculated as follows: 
 
([Uinulin] x urinary flow rate)/ [Pinulin] = GFR 
 
Where: 
[Uinulin] = Urine FITC-inulin concentration 
[Pinulin] = Plasma FITC-inulin concentration  
GFR = Glomerular filtration rate 
 
 Measurement of urine and plasma electrolytes 
Electrolyte analysis was carried out using a Spotchem EL SE-1520 (Arkray, 
Kyoto, Japan). Molar concentration of sodium, potassium and chloride were 
measured in each sample. Urine samples were diluted 1:1 in distilled water 
and terminal plasma left undiluted. Fractional excretion of each analyte was 
calculated as follows with sodium used as an example: 
 
[UNa] x urinary flow rate = eNa  
[PNa] x GFR = filtered load  
(eNa/Filtered load) x 100 = FeNa (%) 
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Where: 
[UNa] = Urine sodium concentration 
[PNa] = Plasma sodium concentration  
eNa = Sodium excretion  
GFR = Glomerular filtration rate 
FeNa = Fractional sodium excretion 
 
 Data analysis and statistics 
Blood pressure data (taken at 1 kHz) were separated into systolic and diastolic 
blood pressure using cyclic measurements on LabChart. Doppler flow and flux 
data were also taken at 1 kHz and average cyclic data taken to remove 
pulsatilty. Data was down sampled prior to analysis and an average of 30 
second periods were taken. All data are mean±SEM. Statistical comparisons 
(Graphpad Prism 6, La Jolla, CA) were made by using one or two-way analysis 
of variance (ANOVA) or t-test, as stated in figure legends along with group 
sizes. For two-way ANOVA, the main effects of the genotype or treatment, the 
interaction between these and time were assessed. The family P value was 
fixed at 0.05. 
 
2.4 Assessment of endothelin and GPR81 interactions 
As previously described (2.3.1), adult male C57BL/6JCrl mice were 
anaesthetised and underwent cannulation of the jugular vein and carotid 
artery. After a 30 minute equilibrium period, blood was sampled from the 
carotid line into lithium-heparinised tubes and separated to plasma. Mice were 
infused for 15 minutes with either 5% D-mannitol vehicle (pH 5) or AZ’5538 
(15 µmol/kg; pH 5) at 0.2 mL/10g bw/hr. At the end of the experiment, another 
blood sample was taken. Mice were then euthanised by cervical dislocation for 
collection of kidneys and thoracic aorta onto dry ice. Plasma and tissues were 
stored at -80oC before use. 
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 Endothelin-1 protein expression 
RIPA buffer (Sigma) was prepared by adding 1 cOmplete mini-protease 
inhibitor tablet (Roche) per 10 mL buffer. Whole kidneys were cut into quarters 
and 700 µL of buffer added to one quarter. Whole aorta samples had 300 µL 
buffer added. All samples underwent homogenisation with a 5 mm stainless 
steel bead at 30 Hz for 90 seconds using a TissueLyserII. Samples were then 
centrifuged at 10,000 g for 10 minutes at 4oC, supernatants then kept on ice.  
 
A BCA assay (Thermo Fisher) was carried out on tissue homogenates. Kidney 
and aorta samples were diluted 1/50 and 1/20 in RIPA buffer, respectively, 
prior to carrying out the assay in duplicate. The assay was conducted 
according to manufacturer’s instructions and total protein content of the 
samples could then be calculated.  
 
Plasma samples along with kidney and aorta homogenates then underwent 
the ET-1 Quantikine ELISA (R&D Systems, Abingdon, UK) according to 
manufacturer’s instructions, in duplicate. Plasma samples were left undiluted 
while kidney homogenates were diluted 1/10 and aortae 1/3 in RIPA buffer.  
 
Aorta and kidney homogenate ET-1 concentrations were normalised to total 
protein. A change in ET-1 concentration in plasma was calculated from before 
and after infusion values. This was due to small sample volumes for plasma.  
 
 Endothelin system gene expression 
Frozen whole kidneys were cut into quarters prior to RNA isolation. 600 µL of 
RLT buffer were added before homogenisation for 1 minute at 30 Hz with a 
stainless steel bead in the TissueLyserII. Samples then underwent the RNeasy 
Mini kit protocol (Qiagen) according to standard protocol instructions. 
Extracted RNA was stored at -80oC. 
 
RNA was quantified and cDNA synthesised from 1 µg of RNA as described 
previously (2.2.2). cDNA samples were diluted 1/40 prior to qPCR using the 
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UPL system (2.2.4). Primers for the genes analysed can be found in Table 2.4. 
Relative gene expression was calculated by normalising to the mean of the 
two housekeeping genes 18S and TBP.  
 
 
Table 2.4 Primers and UPL probes used for qPCR 
Primers designed using UPL Assay Design Centre.  
 
 In vivo blockade of endothelin receptors  
C57Bl/6JCrl mice were anaesthetised and surgically prepared (as previously, 
2.3.1) with two IV lines permitting separate infusion of AZ’5538 and the 
endothelin receptor antagonists. Bostentan (Stratech Scientific), BQ-123 
(Tocris, Bristol, UK); and BQ-788, (Abcam, Cambridge, UK), or their 
corresponding vehicles (0.9% saline for Bosentan and BQ-123; 2.3% or 4.6% 
DMSO for BQ-788) were IV infused at 0.2 mL/10g bw/hr for 40 minutes, for the 
final 15 minutes, AZ’5538 was also infused at 15 µmol/kg. This altered the 
infusion rate to 0.4 mL/10g bw/hr for the final 15 minutes. Bosentan was used 
at 20 and 40 mg/kg65 while BQ-123 and BQ-788 at 1 and 2 mg/kg134. These 
doses were based on previous literature in mice which suggest full receptor 
occupancy.  
 
 Data analysis and statistics 
Differences in protein and mRNA expression of ET-1 and ET-1 related genes 
were analysed by unpaired t-tests. Blood pressure data (taken at 1 kHz) were 
separated into systolic and diastolic blood pressure using cyclic 
measurements on LabChart. Data was down-sampled prior to analysis and an 
average of 30 second periods were taken. All data are mean±SEM. Statistical 
comparisons (Graphpad Prism 6, La Jolla, CA) were made by using two-way 
Coding protein Gene Name Forward Primer Reverse Primer UPL probe number 
18S Rn18s gccgctagaggtgaaattctt cgtcttcgaacctccgact 93
ET-1 Edn1 tccttgatggacaaggagtgt cccagtccatacggtacga 29
ETRA Ednra tgtgagcaagaaattcaaaaattg atgaggcttttggactggtg 34
ETRB Ednrb tcagaaaacagccttcatgc gcggcaagcagaagtagaaa 83
GPR81 Hcar1 ggtggcacgatgtcatgtt gaccgagcagaacaagatgatt 4
HPRT Hprt tcctcctcagaccgctttt aacctggttcatcatcgctaa 95
TBP Tbp gggagaatcatggaccagaa gatgggaattccaggagtca 97
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analysis of variance (ANOVA). Group sizes and statistical analysis used stated 
in figure legends. For two-way ANOVA, the main effect of the treatment was 
assessed, the interaction between these and time with Tukey’s multiple 
comparison test to compare each dose to vehicle control. The family P value 
was fixed at 0.05. 
 
2.5 Wire myography  
 General measurements of vascular tone by wire myography 
Wire myography was used to assess vascular tone in aortae, renal arteries 
and second order mesenteric arteries isolated from adult male mice. All mice 
were culled by asphyxiation with CO2 prior to isolation of the arteries which 
were stored in ice cold physiological salt solution (PSS; 119.0 mM NaCl, 3.7 
mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 25.0 mM NaHCO3, 1.2 mM KH2PO4, 
27.0 μM EDTA, and 5.5 mM D-glucose), cleaned of fat, cut to ~2 mm lengths 
and then mounted onto a wire myograph (Danish MyoTech, Aarhus, 
Denmark). Wells of the myograph were filled with PSS (6 mL), which was 
perfused with 95% O2 and 5% CO2 at 37oC. Basal tone was established for 
renal and mesenteric arteries and set at 7.34 mN for aortae. Due to the larger 
size of aortae, they were cut to exactly 2 mm in length while other arteries were 
measured after mounting. Vessels were then equilibrated for 30 minutes.  
 
To establish vessel contractile capacity over the experimental time course and 
to normalise the absolute contractile force generated by vasoconstrictive 
drugs, vessels were depolarised by replacing the PSS with a high potassium 
physiological salt solution (KPSS; 125 mM KCl) at the beginning and end of 
the experiment. In the majority of studies, all vessels were subjected to 
increasing concentrations of phenylephrine (PE; Sigma 1 nM-1 μM aortae and 
1 nm-3 μM for other vessels), sodium nitroprusside (SNP; Sigma 1 nM-3 μM), 
acetylcholine (ACH; Sigma 1 nM-3 μM) and endothelin-1 (ET-1, Sigma 1 pM-
100 nM). Prior to assessment of vasodilatory drugs (SNP and ACH) vessels 
were preconstricted with PE to the half maximal response. ET-1 dose 
responses were always recorded last, after the final KPSS response due to 
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difficulties in washing ET-1 from the vessels. Drug additions to the PSS bath 
were kept below volumes of 100 µL. 
 
 Effect of AZ’5538 on vascular function 
To assess AZ’5538 toxicity on vessels, adult male C57BL/6JCrl (Charles 
River) were culled and aortae and second order mesenteric arteries isolated 
and mounted. After basal tone was established and responses to KPSS were 
assessed, vessels were incubated for 15 minutes with varying concentrations 
of GPR81 agonist AZ’5538 (15.6,31.3, 62.5, 125 or 250 µM) or vehicle alone 
at the same volume (5% D-mannitol solution, pH 5, Sigma). Group sizes were 
between 2 and 5 and the ability of the vessel to constrict to KPSS before and 
after AZ’5538 were measured. 
 
To determine changes in vascular function with AZ’5538 incubation, 
C57BL/6JCrl mice (n=8) were culled as previously described. Two sections of 
aortae, mesenteric arteries and renal arteries were dissected from each mouse 
and mounted onto the wire myography. Vessels were incubated with 30 µM 
AZ’5538 or 5% mannitol vehicle added to the 6 mL of PSS for 15 minutes 
before washing with PSS. Vessels were then subjected to increasing doses of 
PE, ACH, SNP and ET-1. 
 
Preconstriction of vessels can alter vascular function to certain drugs, such as 
angiotensin II (ANG II), therefore this was assessed for AZ’5538. All three 
vessel types were mounted as previously described and split into two groups 
(n=8 for aorta and mesenteric, n=7 for renal arteries for each group). After 
assessing the vasoconstriction caused by KPSS, half of the wells were 
replaced with normal PSS while others were filled with a 25 mM KCl containing 
PSS to preconstrict vessels. Vessels were allowed to stabilise before a dose 
response carried out of AZ’5538 from 1 nM to 30 µM. Aortic vessels also went 
through this same protocol but with increasing concentrations of ANG II (10 
pM-1 µM, Sigma) rather than AZ’5538. 
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 ETRA blockade ex vivo 
A concentration test for BQ-123 was carried out to assess a dose which 
successfully blocked ET-1 mediated vasoconstriction. Renal arteries from 
C57BL/6JCrl mice were mounted onto the wire myograph. KPSS responses 
were assessed before incubation for 30 minutes with water vehicle or BQ-123 
at 1 µM, 3 µM, or 10 µM added to the PSS in the well (n=4 for each group). 
KPSS response was assessed again after incubation. Vessels were then 
incubated with the same treatment prior to ET-1 dose response to assess 
ETRA blockade.  
 
In a separate experiment, with the aim of preventing AZ’5538-mediated 
vasoconstriction in renal arteries, vessels were incubated with either 1 µM BQ-
123 or vehicle for 30 minutes followed by addition of 30 µM AZ’5538 or vehicle 
(n=8 for vehicle only and BQ-123 + AZ’5538, n=15 for vehicle + AZ’5538).  
 
 Assessment of vascular function in Gpr81-/- mice 
Adult male Gpr81-/- and WT littermates were culled via asphyxiated with CO2. 
Mesenteric and renal arteries were isolated and mounted onto the wire 
myograph (n=5-6). All vessels were assessed for responses to KPSS (at the 
beginning and end of experiment), PE, ACH, SNP, ET-1 and a 15 minute 
incubation with 30 µM AZ’5538. 
 
In separate experiments, renal arteries from Gpr81 null and WT mice were 
administered with increasing concentrations of AZ’5538 (1 nM-30 µM) (n=10-
11 from 6 mice) before and after KPSS. 
 
 Statistical analysis for wire myography 
Data was obtained using LabChart Software (AD Instruments) and taken at 1 
Hz. All analysis was carried out using GraphPad Prism 8. Responses to KPSS, 
both absolute maximum mN value and percentage change from the beginning 
and end of the experiment were analysed by unpaired t-tests. Contractility data 
is presented as a percentage of the maximum KPSS response and dilatory as 
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a percentage of the vessel’s preconstriction with PE both against –log of the 
molar drug concentration. All data are shown as mean±SEM. Non-linear 
regression provided dose response curves for PE, SNP, ACH, ET-1 and 
AZ’5538. Dose responses between groups were compared using two-way 
ANOVA as well as comparing EC/IC50 and %E/Imax from the non-linear 
regressions formed using an extra sun-of-square F test. BQ-123 toxicity data 
was compared using a one-way ANOVA with a Dunnett’s post hoc test. All 
statistical analysis details and group sizes are in the figure legends. 
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Chapter 3 - Expression of 
GPR81 and in vivo receptor 
activation  
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3.1 Introduction 
Although it has been known for over a decade that GPR81 is expressed in the 
kidney as well as other cardiovascular tissues30, the function in these tissues 
is still not understood. With the exception of adipocytes, there is a lack of data 
on cell-type specific localisation of the receptor. There have been previous 
studies implying expression of the receptor in the vasculature42, in particular in 
vascular smooth muscle93. There have also been reports of a potential 
vasoactive role of the receptor, with a more recent study finding that activation 
of GPR81 in vivo caused an increase in mean arterial blood pressure (MABP) 
of ~15 mmHg in both rats and dogs65. I aimed to define the potential role of 
GPR81 activation in blood pressure regulation. 
 
To help understand the physiological role of GPR81, my collaborators at 
AstraZeneca (Gothenburg, Sweden) have provided the specific GPR81 
agonist AZ13415538 (referred to as AZ’5538). In vitro EC50 values for GPR81 
are 74 nM, 310 nM and 180 nM for adipocytes from human, rat and mouse, 
respectively. Along with this compound, AstraZeneca have also provided the 
Gpr81-null mouse line. Homozygote Gpr81-/- mice have a global deletion of the 
single exon Gpr81 gene and are on a C57BL/6NCrl background. There have 
been no reported adverse phenotypes of this genetic deletion65. This mouse 
line allows confirmation of on-target GPR81 effects of AZ’5538 in the in vivo 
studies. 
 
The objective of this chapter was to localise the receptor in the kidney and 
vasculature and to use AZ’5538 as a tool to investigate the effects of GPR81 
activation on blood pressure and renal haemodynamics in mice. 
 
I hypothesise is that Gpr81 is expressed within the vasculature, including that 
of the kidney, and that activation of GPR81 by AZ’5538 will cause specific 
cardiorenal effects. I aimed to address this hypothesis by, firstly, determining 
the expression of Gpr81 mRNA in whole kidney and artery homogenate 
followed by localising Gpr81 expression in specific areas of the kidney, aorta 
 43 
and renal arteries. Next I will investigate the effect of acute AZ’5538 infusion 
on blood pressure, heart rate, renal blood flow and kidney function in wildtype 
C57BL/6JCrl mice. And finally assess the specificity of any changes seen with 
AZ’5538 infusion by utilising the Gpr81-/- mouse as a negative control. 
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3.2 Results 
 Renal and vascular expression of Gpr81 
End point PCR was used to identify Gpr81 mRNA expression in the aorta, 
renal and mesenteric arteries of wildtype C57BL6/JCrl mice (Figure 3.1, see 
Table 2.1 for primer details). 
 
Figure 3.1 Gpr81 expression in the mouse vasculature by end point PCR 
RNA was extracted and reverse transcribed from C57BL/6JCrl mouse vessels. 
Negative controls were samples where reverse transcription enzyme or RNA were left 
out at the cDNA conversion step. All samples underwent end point PCR before gel 
electrophoresis. n=4 for all vessel types, pooled from 2 mice for renal arteries and 
mesenteric arteries. 
 
qPCR was also utilised as a second technique to confirm Gpr81 expression in 
the vasculature. Expression for Gpr81 was found in aorta, renal and 
mesenteric arteries (Figure 3.2). 
  
300bp -
400bp -
Aorta
Renal 
arteries
Mesenteric 
arteries -RT -RNA
- 360bp
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Figure 3.2 Gpr81 expression in the mouse vasculature by qPCR 
RNA was extracted and reverse transcribed from C57BL/6JCrl mouse arteries. n=4 
for all, pooled from 2 mice for renal arteries and mesenteric arteries. Gene expression 
was normalised to the average of housekeepers, 18S and β-actin. 
 
RNAscope in situ hybridization was used to localise GPR81 within kidney, 
aorta and renal artery sections. This was carried out in Gpr81-/- and WT 
littermate mice. In whole kidney sections, no positive staining was found in 
Gpr81-/- mice (Figure 3.3 and Figure 3.4).  Gpr81 was expressed in both the 
cortex and medulla of the WT animal kidneys (Figure 3.3 and Figure 3.4). The 
staining in the cortex was localised mainly in the glomeruli (Figure 3.3), 
particularly at the vascular poles (indicated by the stars), consistent with 
localisation in afferent or efferent arterioles.  
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Figure 3.3 Gpr81 expression in the kidney glomerulus by RNAscope in situ 
hybridisation 
Mouse kidney cut longitudinally prior to in situ hybridisation. Positive Gpr81 mRNA 
expression shown by red punctuated dots, nuclei stained blue and tubules pale pink. 
Expression found in wildtype mouse glomeruli of the kidney cortex (A, C and E) where 
the star indicates staining at arterioles of the glomerulus. No staining seen in Gpr81-/- 
mouse kidney cortex (B, D and F). Scale bars represent 25 μm. 
(A) (B)
(C) (D)
(E) (F)
Gpr81+/+ Gpr81-/-
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Expression for Gpr81 was found in the medulla of kidney sections and did not 
colocalise with the nuclear stain (Figure 3.4).  
 
 
Figure 3.4 Gpr81 expression in the kidney medulla by RNAscope in situ 
hybridisation 
Mouse kidney cut longitudinally prior to in situ hybridisation. Positive Gpr81 mRNA 
expression shown by red punctuated dots and nuclei stained blue. Gpr81 expression 
found in the medulla of the kidney in wildtype mice (A and C) while no staining is seen 
in Gpr81-/- mouse kidney medulla (B and D). Scale bars represent 50 µm. 
  
(A) (B)
(C) (D)
Gpr81+/+ Gpr81-/-
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Although at lower levels, some staining to indicate Gpr81 expression was also 
present in the blood vessels in the kidney cortex in wildtype mice (Figure 3.5). 
 
 
Figure 3.5 Gpr81 expression in vessels in the kidney cortex of wildtype mice by 
RNAscope in situ hybridisation 
Mouse kidney cut transverse prior to in situ hybridisation. Positive Gpr81 mRNA 
expression shown by red punctuated dots, nuclei stained blue and tubules are pale 
pink. All panels show vessels in the kidney cortex of Gpr81+/+ mice. Scale bars 
represent 50 µm. 
 
Both in the aorta and renal arteries (Figure 3.6 and Figure 3.7), positive 
staining is seen in the medial layer of the arteries, consistent with localisation 
to vascular smooth muscle cells, indicated by black arrows. No staining was 
visible in arteries from Gpr81-/- mice (Figure 3.6and Figure 3.7 (B) and (D) for 
both). 
 
(A) (B)
(C) (D)
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Figure 3.6 Gpr81 expression in the aorta of mice by RNAscope in situ 
hybridisation 
Positive Gpr81 mRNA expression shown by red punctuated dots and nuclei stained 
blue. Arrows indicate Gpr81 staining in Gpr81+/+ mouse aortae (A and C) while no 
staining is seen in Gpr81-/- vessels (B and D). Scale bars represent 20 µm for all. 
(A) (B)
(C) (D)
Gpr81+/+ Gpr81-/-
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Figure 3.7 Gpr81 expression in the renal arteries of mice by RNAscope in situ 
hybridisation 
Positive Gpr81 mRNA expression shown by red punctuated dots and nuclei stained 
blue. Arrows indicate Gpr81 staining in Gpr81+/+ mouse renal arteries (A and C) while 
no staining is seen in Gpr81-/- vessels (B and D). Scale bars represent 20 µm. 
 
 In vivo activation of GPR81 with AZ’5538 in wildtype mice 
Heart rate (HR), systolic (SBP) and diastolic (DBP) blood pressure were 
measured in terminally anesthetized male C57BL/6JCrl mice. Baseline values 
were 284±15 bpm, 85.6±3.8 mmHg, and 68.9±4.6 mmHg for HR, SBP, and 
DBP, respectively. AZ’5538 significantly increased both SBP and DBP 
compared to 5% mannitol vehicle (Figure 3.8(A) and (B)). The peak blood 
pressure increase was 13.4±1.6 mmHg and 11.3±1.1 mmHg for SBP and DBP 
respectively (Figure 3.8(D)). Heart rate decreased with infusion of AZ’5538; 
(A) (B)
(C) (D)
Gpr81+/+ Gpr81-/-
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5% mannitol vehicle infusion caused a slight tachycardia (Figure 3.8(C) and 
(E)).  
 
Figure 3.8 AZ’5538 infusion increases blood pressure and decreases heart rate 
Vehicle and GPR81 agonist AZ’5538 were infused intravenously into C57BL/6J mice 
over a 15 minute period at 1µmol/kg/min. Activation of GPR81 increased (A) systolic 
and (B) diastolic blood pressure and decreased (C) heart rate compared to 5% 
mannitol vehicle control, all assessed by two-way ANOVA where the P value given is 
that of the drug treatment. At the end of the infusion, differences in (D) systolic and 
diastolic blood pressure and (E) heart rate were analysed by paired t tests. (F) Area 
under the curve was assessed for the blood pressure responses. All data are 
mean±SEM from baseline, n=6 
 
All mice received a second infusion of AZ’5538, 35 minutes after the first 
administration. The pressor response to the second administration was 
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attenuated, particularly in DBP (Figure 3.9), suggesting receptor de-
sensitization. 
 
Figure 3.9 A second infusion of AZ'5538 has a blunted pressure response 
C57BL/6JCrl mice were infused with AZ’5538 for 15 minutes with a 20 minute window 
of no infusion followed by a second 15 minute infusion. Traces show (A) systolic and 
(B) diastolic blood pressure. All data are mean±SEM from baseline, n=6. 
 
Renal blood flow (RBF) was measured in two different groups of mice by two 
different methods. First, by direct Doppler ultrasound with a probe around the 
right renal artery. Baseline RBF was 0.60±0.11 mL/min which was significantly 
decreased with AZ’5538 infusion by ~50% (Figure 3.10(A), plateau of -
0.33±0.12 mL/min; ANOVA drug treatment P=0.027; time and interaction 
P<0.0001). Renal vascular resistance (RVR) was calculated by normalising to 
mean arterial blood pressure and this was significantly increased (Figure 
3.10(B), ANOVA drug treatment P=0.019; time and interaction P<0.0001). 
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Figure 3.10 Renal blood flow is decreased with AZ'5538 infusion measured by 
Doppler flow probe 
C57BL/6JCrl mice were infused with 5% mannitol vehicle followed by AZ’5538. (A) 
change in renal blood flow measured by Doppler ultrasound flow probe around the 
right renal artery. (B) Renal vascular resistance calculated by normalising to blood 
pressure. All data are mean±SEM from baseline, n=4 and analysed by two-way 
ANOVA where the P value given is that of the drug treatment. 
 
Renal blood pressure was also measured by pulse-wave Doppler ultrasound. 
Baseline velocity was 275.2±10.4 mm/sec which was decreased by ~30% 
(Figure 3.11, peak decrease of -181.8±12.8 mm/sec; ANOVA drug treatment 
P=0.0002, time and interaction P<0.0001).  
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Figure 3.11 Renal blood flow is decreased with AZ'5538 infusion measured by 
pulse-wave Doppler ultrasound 
C57BL/6JCrl mice were infused with 5% mannitol vehicle followed by AZ’5538. Pulse-
wave Doppler ultrasound used to measure change in right renal artery blood velocity 
Data are mean±SEM from baseline, n=4 and analysed by two-way ANOVA where the 
P value given is that of the drug treatment. 
 
Mice were infused with a solution containing FITC-inulin, permitting the 
calculation of GFR by inulin clearance. After a baseline urine collection, mice 
were infused either with AZ’5538 or vehicle and data are presented as the net 
change (delta or ) from baseline values. Urine flow rate was significantly 
affected by AZ’5538: the  value was significantly different from zero in the 
drug treated group but not vehicle (Figure 3.12(B)). Baseline GFR was lower 
in the vehicle treated group (Figure 3.12(C), vehicle=119.0±7.7 µL/min 
AZ’5538=148.4±18.1 µL/min). Vehicle infusion had no effect on GFR; in 
contrast AZ’5538 reduced GFR and the  was significantly different from zero. 
(Figure 3.12(D)). 
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Figure 3.12 Kidney function is decreased with AZ’5538 infusion 
Mice were infused continuously with 0.25% FITC-inulin with either 5% mannitol vehicle 
or AZ’5538 at. Urine was collected to measure (A) flow rate and (B) changes in urine 
flow (C) GFR and (D) the change in GFR from baseline for vehicle or AZ’5538. (B) and 
(D) analysed by one sample t and Wilcoxon test to assess if changes were different 
from 0. All data are mean±SEM from baseline, n=8. 
 
AZ’5538 did not change fractional sodium chloride and plasma concentrations 
of Na and Cl were not different between groups (Figure 3.13(A-D)). Plasma 
potassium was significantly higher in mice receiving AZ’5538 but it is not 
certain whether this was an effect of the drug since plasma K was measured 
only in a large, final blood sample and was not able to be measured accurately 
in the urine samples (Figure 3.13(E)).  
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Figure 3.13 Changes in plasma and urine electrolyte concentration with AZ’5538 
infusion 
C57BL/6JCrl mice were infused with either 5% mannitol vehicle or 1 µmol/kg/min 
AZ’5538. Terminal plasma was analysed for (A) sodium, (C) chloride and (E) 
potassium concentration. Urine was collected pre and post infusion and the change in 
fractional (B) sodium and (D) chloride excretion measured by normalising to GFR. All 
data are mean±SEM from baseline, n=8 and analysed by unpaired t-test. 
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 Cardiorenal effects of AZ’5538 and GPR81 specificity 
At baseline, under terminal anaesthesia, there were no differences between 
male Gpr81-/- mice and WT littermates in SBP, DBP, HR, RBF (measured by 
Doppler flow probe) or GFR (Table 3.1). 
 
 
Table 3.1 Gpr81-/- and wildtype littermates show no differences in baseline 
cardiorenal parameters 
Systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), renal 
blood flow (RBF; right kidney) and glomerular filtration rate (GFR; both kidneys) in 
Gpr81+/+ and Gpr81-/- littermates under terminal anaesthesia. Data are mean±SEM 
analysed by unpaired t-test. For SBP, DBP and HR n=10. RBF and GFR were 
measured in separate groups of mice (n=5 for RBF; n=6 for GFR). 
 
In the wildtype mice, infusion of AZ’5538 increased SBP (Figure 3.14 (A), 
P<0.0001 genotype, time and interaction) and decreased HR (Figure 3.14 (B) 
ANOVA genotype P=0.025, time P=0.003 and interaction P<0.0001). AZ’5538 
was without effect in Gpr81-/- mice. Similarly, RBF, measured by Doppler 
ultrasound probe, decreased significantly with AZ’5538 infusion in WT mice 
but remained unchanged in Gpr81-/- mice (Figure 3.14 (C), ANOVA genotype 
P=0.008 interaction and time P<0.0001). Renal vascular resistance, calculated 
from RBF and BP, did not show significant differences between genotypes 
(Figure 3.14 (D), ANOVA genotype P=0.151, time P=0.022 and interaction 
P=0.0002). Perfusion in the cortex and medulla of the right kidney was 
measured using Doppler needle probes. AZ’5538 induced a significant 
reduction in perfusion of the cortex, but only in WT mice (Figure 3.14 (E), 
genotype P=0.0003, time and interaction P<0.0001). Medullary flux was also 
Gpr81+/+ P= Gpr81-/-
SBP (mmHg) 73.3±18.8 0.749 71.0±17.3
DBP (mmHg) 59.7±14.3 0.990 59.6±17.3
HR (bpm) 281±57 0.612 293±48
RBF (mL/min) 0.63±0.40 0.461 0.48±0.18
GFR (µL/min) 270.2±28.4 0.587 289.0±17.9
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reduced in the medulla of WT mice but not in the Gpr81-/- (Figure 3.14 (F), 
genotype P=0.070, time and interaction P<0.0001). Overall, the blood 
pressure and blood flow effects were qualitatively similar between Gpr81+/+ 
and C57BL/6JCrl mice although a higher increase in systolic blood pressure 
was seen in the C57BL/6JCrl mice. 
 
 
Figure 3.14 Infusion of AZ’5538 into Gpr81-/- mice causes no cardiorenal effects 
Gpr81-/- mice and WT littermates were anaesthetised and infused with AZ’5538 at 15 
µmol/kg. Changes in (A) blood pressure and (B) heart rate were measured via the 
carotid artery (A and B, n=10). Renal blood flow assessed by Doppler flow probe 
around the right renal artery and normalised to MABP to calculate renal vascular 
resistance (C and D, n=5). In other animals, cortex and medulla perfusion was 
measured by Doppler needle probes (E and F, n=6). All data are mean±SEM from 
baseline and analysed by two-way ANOVA where the P value given is that of genotype 
differences. 
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In a separate experiment, the effect of GPR81 activation on glomerular 
filtration rate (GFR) was assessed using inulin clearance. Baseline GFR was 
not different between genotypes (Table 3.1). AZ’5538 caused a significant 
decrease in GFR from baseline (Figure 3.15(D), GFR = -125.3±48.4 µL/min; 
P=0.001; n=6) in WT mice. The GPR81 agonist did not significantly change 
GFR in Gpr81-/- animals (Figure 3.15(D), GFR = -39.0±83.2 µL/min; P=0.303; 
n=6). 
 
 
Figure 3.15 Infusion of AZ’5538 into Gpr81-/- mice does not alter kidney function 
Gpr81-/- mice and WT littermates were infused continuously with 0.25% FITC-inulin 
and AZ’5538 at 1 µmol/kg/min. Urine was collected to measure; (A) urine flow, (B) 
changes in urine flow, (C) GFR, and (D) the change in GFR from baseline for vehicle 
or AZ’5538. (B) and (D) analysed by one sample t and Wilcoxon test to assess if 
changes were different from 0. All data are mean±SEM from baseline, n=6. 
 
There were no differences seen between Gpr81-/- and WT littermates in 
terminal plasma concentrations of sodium or chloride (Figure 3.16 (A) and (C)). 
There were also no differences between genotypes for the baseline excretion 
rate or change in fractional excretion of the same electrolytes (Table 3.2 and 
Figure 3.16 (B) and (D). There was however a difference in the terminal plasma 
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concentration of potassium (Figure 3.16 (E)) with higher levels seen in WT 
animals (WT = 4.58±0.16 mol/L, KO = 3.83±0.19 mol/L, P=0.012). This is the 
same trend that was seen in C57BL/6JCrl mice between vehicle and AZ’5538 
suggesting this is GPR81 specific.  
 
 
Table 3.2 No difference between the baseline urinary excretion rate of sodium 
and chloride in Gpr81-/- and wildtype littermates 
Baseline urinary excretion rate of sodium and chloride corrected to urinary flow rate of 
Gpr81-/- mice and wildtype litter mates. All data are mean±SEM from baseline, n=6 and 
analysed by unpaired t-test. 
Gpr81+/+ P= Gpr81-/-
Sodium (nmol/min) 731±205 0.651 897±290
Chloride (nmol/min) 1122±209 0.657 1286±292
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Figure 3.16 Changes in plasma and urine electrolyte concentration with AZ’5538 
infusion in Gpr81-/- mice 
Gpr81-/- mice and WT littermates were infused with 1 µmol/kg/min AZ’5538. Terminal 
plasma was analysed for (A) sodium, (B) chloride and (C) potassium concentration. 
Urine was collected pre and post infusion and the change in fractional (D) sodium and 
(E) chloride excretion measured by normalising to GFR. All data are mean±SEM from 
baseline, n=6 and analysed by unpaired t-test. 
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3.3 Discussion 
In this chapter, the renal and vascular expression were assessed along with 
the in vivo activation of GPR81. Expression of Gpr81 mRNA was found in 
whole arteries of wildtype mice and further identified in vascular smooth 
muscle cells of the aorta and renal arteries, along with the glomeruli and 
vessels of the kidney cortex and throughout the medulla. Infusion of the 
GPR81 specific agonist AZ’5538 into wildtype mice caused a rapid increase in 
BP, decreased HR, RBF and GFR. Utilising the Gpr81-/- mouse, the specificity 
of the acute in vivo cardiorenal effect of AZ’5538 infusion was confirmed along 
with a Gpr81 specific reduction in cortical and medullary perfusion.  
 
 Renal and vascular expression of Gpr81 
Initial studies that found lactate to be the endogenous ligand for GPR81 also 
presented the range of tissues that the receptor is expressed in. The majority 
of GPR81 expression is found in adipose tissue, with higher levels in brown 
than white adipose30. Gpr81 mRNA expression across a range of non-adipose 
tissue was also reported, with expression in the highly vascularized tissues of 
heart, skeletal muscle and kidney being ~10% of that in adipocytes30. Another 
study did not detect GPR81 expression in skeletal muscle42, although 
expression may be below the detection threshold of the GPR81-RFP reporter 
used in these mice.  
 
With the knowledge that the GPR81-RFP mouse had low levels of 
expression42 and having received anecdotal advice that the GPR81 antibodies 
had cross-reactivity with other GPCRs of the same family (Kristina Wallenius, 
personal communication), end point PCR and qPCR were used as a starting 
point followed by in situ hybridisation using the RNAscope system to determine 
the vascular and renal expression of Gpr81 mRNA. Housekeepers for qPCR 
were determined by assessing a panel in each vessel type. 18S and β-actin 
had the most stable expression in all artery types. Robust Gpr81 mRNA was 
detected each of the three arteries examined using both methods of detection. 
Although not shown here, in my MSc mini project based on GPR81, a positive 
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control of white adipose and negative control of adipose from a Gpr81-/- mouse 
was used to confirm specificity of the primers and PCR135. In situ hybridization 
further localized Gpr81 to the smooth muscle layer of arteries, consistent with 
fluorescent-reporter expression in the vessel wall of pial arteries in the mouse 
brain42 and with single cell RNA sequencing experiments detecting the 
receptor in cerebral and lung vascular smooth muscle cells93. Within the 
kidney, Gpr81 was additionally expressed in glomerular arterioles and within 
perivascular cells, particularly in the renal medulla. A limitation is that co-
localisation has not yet been carried, but others have reported renal afferent 
arteriole expression in the mouse and dog65. In the cerebral microcirculation, 
GPR81 colocalizes with PDGFR  expressing cells and in leptomeningeal 
cells42, i.e. in cell populations interacting closely with the capillary 
microcirculation supporting our findings within the vasculature.  
 
 AZ’5538 induced GPR81-specific cardiorenal effects 
There are many states in which GPR81 would be activated by increased 
circulating lactate levels including tissue ischemia, cardiac arrest, liver failure, 
pharmacological agents and of course, hypoxia80. The study of GPR81 using 
endogenous ligand lactate is difficult due to many off target effects, however, 
the recent development of potent GPR81 agonists to treat dyslipidemia65,66,136 
provide tools with which to probe the cardiovascular physiology of 
GPR8165,66,136. In a recent study, structurally distinct compounds developed by 
AstraZeneca increased SBP by ~15mmHg in rats and dogs65, the pressor 
effect in mice was much less pronounced (~5 mmHg) but data from Gpr81-/- 
mice suggested this was GPR81-mediated. Our studies in mice unequivocally 
demonstrate that AZ’5538 increases blood pressure dependent on the 
expression of GRP81. No differences were seen at baseline between Gpr81-/- 
and wildtype littermates however this is problematic to interpret as these mice 
were under terminal anaesthetic, although previous reports also report no 
phenotypic differences between genotypes65. A surprising finding was that 
AZ’5538 caused hyperkalaemia in a GPR81-dependent manner. Due to this 
rapid effect, it is suspected this is redistribution of potassium across cells rather 
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than a balance problem. It is also unexpected to see that there were no 
alterations in renal sodium handling, as this would be expected. A decrease in 
GFR along with RBF would suggest there should also be alterations in sodium 
excretion however these were not seen here. However, it could be that this 
response is delayed and therefore not seen due to the short time frame 
although there is a change in urine flow rate seen in this time frame. I have 
further shown that GPR81 activation reduces flow through the renal artery, 
perfusion of the cortex (and, to a lesser extent, the renal medulla) and 
decreases GFR. Since BP is rising, the data are likely to reflect 
vasoconstriction at the level of the renal artery and afferent arteriole, causing 
a change in total peripheral resistance. This is supported by the rapid onset of 
the blood pressure increase and the decrease in heart rate. It is difficult to 
unambiguously interpret the regional hemodynamic effects of GPR81 
activation but in our experience, regional blood flow effectively autoregulates, 
at least in the cortex137. Given the expression of the receptor in perivascular 
cells, these data may reflect regulation of capillary flow by GPR81 activation, 
but this is speculative. Of note, there were not any difference in basal blood 
pressure or blood flow in Gpr81-/- mice identified, supporting the concept that 
the receptor is functionally quiescent at physiological concentrations of lactate 
137. 
 
There are still key pieces of information missing to completely understand the 
GPR81 mediated in vivo effects. Firstly, delivery of AZ’5538 directly to the 
kidney, through the renal artery would be beneficial. This is a technique 
currently being worked up but is yet to be fully optimised. This would show us 
if renal delivery is sufficient to cause vasoconstriction of the renal artery and a 
decrease in renal blood flow or whether this is a systemic effect as seen with 
IV delivery via the jugular vein. It is also necessary to rule out a CNS effect of 
GPR81 activation, particularly as it is known that there is expression in the 
brain43. To confirm the increased blood pressure is not due to increased 
sympathetic drive, ganglionic blockade using hexamethonium could be infused 
prior to AZ’5538 and the blood pressure response analysed.  
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In the studies in this chapter, male adult Gpr81-/- and wild type littermates were 
used. Therefore, a limitation is that both female and heterozygote mice were 
not examined. In the studies carried out by AstraZeneca, they also only used 
male mice and rats while the dog studies included both males and females65. 
Although it was not feasible in the time frame of this PhD to analyse both sexes 
and all three genotypes, it would be very interesting to repeat these 
experiments with both. I expect there would be a lower response in 
heterozygote mice to AZ’5538 but whether this would be significantly different 
is of interest.  
 
 Molecular mechanisms of GPR81 activation 
The cellular mechanism underpinning GPR81-mediated vasoconstriction is 
not known. The expression profile of GPR81 which has been discussed in this 
chapter suggests involvement of lactate/GPR81 in vascular function, similar to 
that reported for other GPCRs activated by metabolic intermediates. Thus, 
niacin, which activates GPR109a, reduces the production of reactive oxygen 
species by arterial endothelial cells138 and also promotes vasodilation by 
stimulating prostaglandin production139. For lactate/GPR81, however, 
functional data are limited. Increasing lactate concentration in the brain, either 
through exercise or by exogenous administration, promotes angiogenesis42. 
This effect is GPR81-dependent since lactate-induced angiogenesis does not 
occur in knockout mice. Lactate also vasoconstricts rat retinal microvessels92 
but it is not known whether this is GPR81-mediated or relates to other actions 
of lactate on cell membrane transporters92. In a similar way it has been shown 
that lactate stimulated GPR81 on Müller cells of the mouse retina contributes 
to new blood vessel formation and GPR81-null mice show reduced 
vascularisation in the retina140. Infusion of very high concentrations of lactate 
increases blood pressure in rats89 but this most likely reflects the 
sympathoexcitation induced by panic, rather than activation of GPR81 in blood 
vessels 92.  
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In adipocytes, GPR81 couples to Gi, downregulating cAMP production and 
protein kinase A signaling141 and this signalling pathway influences lipolysis 
inhibition. There is evidence to suggest that activation of Gi pathways have 
vascular influence, in particular due to the lowering of intracellular cAMP 
levels. For example, succinate activation of GPR91, which is coupled to Gi, 
acutely increases blood pressure in rats142 and has direct effects on arterial 
contractility143. In a similar way, activation of Gi pathways by GPCR kinase 5 
(GK5) lowers cAMP in vascular smooth muscle, causing a sustained increase 
in blood pressure144. Activation of A1 receptors by adenosine also constricts 
the renal afferent arteriole by a Gi-mediated cascade within smooth muscle 
cells145, this is of particular interest due to our suggestion of GPR81 expression 
in the renal arterioles and particularly, in smooth muscle cells of these vessels. 
Activation of these receptors is also known to cause hyperkalaemia146, an 
effect seen with AZ’5538. 
 
Reciprocally, mechanisms which increase cAMP have been shown to promote 
relaxation of vessels. This has been demonstrated in rat mesenteric147 and pig 
interlobar148 arteries using a range of pharmacological agents to increase 
intracellular cAMP. In rat mesenteric arteries, it was shown that increased 
cAMP decreased intracellular calcium concentration in smooth muscle cells 
which caused the relaxation of vessels147. 
 
This chapter indicates that GPR81 activation regulates macro- and 
microvascular perfusion within the kidney. The physiological requirement for 
such a system is not clear since this would operate to vasoconstrict regions of 
high anaerobic cellular metabolism. Perhaps it serves to constrain and 
regulate flow into relatively ischemic areas of the kidney, mitigating against 
hyperaemic damage. Importantly, renal tissue lactate levels are high in 
conditions of ischemic injury and other studies have shown the potential 
benefit of GPR81 antagonism in ischemic brain injury72 and cancer73,74,149. 
Thus, blockade of the GPR81 system could be therapeutically tractable to 
prevent vascular damage during ischemic renal injury. Further detail into the 
 67 
mechanism of action of GPR81-mediated vasoconstriction will aid in the 
therapeutic potential of the receptor73,74,149. 
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 Summary of chapter findings 
− Gpr81 mRNA expression was found in whole artery and kidney 
homogenates  
− Specifically, Gpr81 was localised to the arterioles of the kidney 
glomeruli, the medulla and the smooth muscle of the aorta and renal 
arteries 
− No expression of Gpr81 mRNA was found in the Gpr81-/- mouse 
− AZ’5538 infusion caused a rapid increase in BP, decrease in HR, RBF, 
capillary perfusion and GFR 
− All in vivo effects were GPR81 specific as they were not seen in the 
Gpr81-/- mouse 
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Chapter 4 - Investigating the 
interaction between GPR81 
and the endothelin system 
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4.1 Introduction 
Having demonstrated that the blood pressure and haemodynamic effects of 
AZ’5538 were GPR81-mediated, the next aim was to understand the 
mechanisms behind these actions. In 2017, Wallenius et al. published data 
showing that the pressor effect of AZ’5538 (referred to there as AZ2) could be 
partially prevented by bosentan, a mixed endothelin A and B receptor 
antagonist65. My studies localised GPR81 expression in the vascular smooth 
muscle, and the rapid increase in BP and reduction in renal blood flow support 
the concept of peripheral vasoconstriction and an association between GPR81 
and ET-1, the most potent endogenous vasoconstrictor101. 
 
I hypothesised that activation of GPR81 in vivo using AZ’5338 would cause 
activation of the endothelin system and that inhibition of this pathway would 
prevent the pressor effect of GPR81 activation. In this chapter, I collected 
tissue and plasma from mice treated with AZ’5538 or vehicle to measure ET-
1 protein or mRNA expression of associated genes. I also blocked endothelin 
receptors, using both mixed and specific antagonists, to assess the impact on 
the AZ’5538 induced rise in BP. 
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4.2 Results 
 Expression of endothelin system components with GPR81 
activation 
ET-1 concentration was measured in the plasma before and after infusion of 
AZ’5538 or vehicle and is presented as the change in ET-1 concentration. 
There was a significant increase in plasma ET-1 (Figure 4.1, Vehicle 0.13±0.10 
pg/mL and AZ’5538 0.44±0.10 pg/mL, P=0.045). 
 
 
 
Figure 4.1 Infusion of AZ’5538 increases circulating ET-1 
C57BL/6JCrl mice were anaesthetised and infused with either vehicle or 1 µmol/kg/min 
AZ’5538 for 15 minutes. ET-1 protein was measured by ELISA in plasma samples (A) 
before and after infusion and (B) change in protein level calculated. Data are 
mean±SEM analysed by unpaired t-test, n=8. 
 
There were no differences between terminal ET-1 concentrations in kidney and 
aorta homogenates from mice treated with vehicle or AZ’5538 (Figure 1.2 (A) 
and (B), respectively). 
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Figure 4.2 Infusion of AZ’5538 does not change ET-1 levels in the tissue 
C57BL/6JCrl mice were anaesthetised and infused with either vehicle or 1 µmol/kg/min 
AZ’5538 for 15 minutes. ET-1 protein was measured by ELISA in (A) whole kidney 
homogenate and (B) aorta homogenate and normalised to total protein. Data are 
mean±SEM analysed by unpaired t-test, n=8. 
 
In terms of gene expression, AZ’5538 infusion did not alter expression of 
GPR81 or ETRA (Ednra) in the whole kidney (Figure 1.3 (A) and (C)). 
However, renal expression of ET-1 (Edn1) and ETRB (Ednrb) were both lower 
in mice that had received an infusion of AZ’5538 (Figure 1.3 (B) and (D)). 
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Figure 4.3 Infusion of AZ’5538 alters mRNA expression of the endothelin system 
C57BL/6JCrl mice were anaesthetised and infused with either vehicle or 1µmol/kg/min 
AZ’5538 for 15 minutes. Gene expression was measured by qPCR in whole kidneys 
for (A) Gpr81 (GPR81), (B) Edn1 (ET-1), (C) Ednra (ETRA) and (D) Ednrb (ETRB) 
and normalised to housekeeper expression  (Rn18s and Tbp). Data are mean±SEM 
analysed by unpaired t-test, n=8. 
 
 Blockade of endothelin receptors and GPR81 activation in 
vivo 
To assess functional cross talk between GPR81 and the endothelin system, 
C57BL/6JCrl mice were pre-treated with the mixed endothelin receptor 
antagonist, bosentan prior to infusion of AZ’5538. Bosentan alone at 20 mg/kg 
or 40 mg/kg had no effect on systolic or diastolic blood pressure compared to 
vehicle (Figure 4.4).  
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Figure 4.4 Mixed endothelin receptor antagonist Bosentan has no effect on 
baseline BP 
Vehicle and two doses of Bosentan were infused intravenously into C57BL/6JCrl mice 
over a 25 minute period. (A) Systolic and (B) diastolic blood pressure was recorded 
during infusion of Bosentan. Data are mean±SEM from baseline and were analysed 
by two-way ANOVA with the P value given that of the drug treatment, n=5. 
 
Bosentan pre-treatment at either 20 mg/kg or 40 mg/kg partially diminished the 
pressor effect of AZ’5538 (Figure 4.5, Bosentan treatment P=0.024, time 
P<0.0001 and interaction P=0.064). Multiple comparisons statistics showed 
significant differences between vehicle treated mice and Bosentan at the lower 
dose of 20 mg/kg but not the higher dose for both SBP and DBP (Table 4.1). 
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Figure 4.5 Effect of mixed endothelin receptor antagonist Bosentan on GPR81 
mediated blood pressure changes 
Vehicle and two doses of Bosentan were infused intravenously into C57BL/6JCrl mice 
over a 25 minute period prior to being infused alongside AZ’5538 for 15 minutes at 1 
µmol/kg/min. Bosentan at 20 mg/kg and 40 mg/kg were compared to vehicle. (A) 
Systolic and (B) diastolic blood pressure were recorded. All data are mean±SEM from 
baseline, n=5, analysed by two-way ANOVA with Tukey’s multiple comparisons test 
where the P value given is that of antagonist treatment. 
 
 
Table 4.1 Multiple comparison statistics for Bosentan pre-treatment 
Data were analysed by two-way ANOVA with Tukey’s multiple comparisons test. P 
values given for the main effect of the bosentan pre-treatment compared to vehicle for 
both systolic (SBP) and diastolic (DBP) blood pressure. Significant values given in red. 
n=5. 
 
Vehicle vs 
20mg/kg
Vehicle vs 
40mg/kg
Bosentan
SBP 0.017 0.071
DBP 0.021 0.081
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To resolve this effect further, the experiment was repeated using pre-treatment 
with either BQ-123, to block the endothelin A receptor (ETRA) or BQ-788, to 
block the endothelin B receptor (ETRB). BQ-123 or BQ-788 alone, at both 
doses, did not change baseline BP (Figure 4.6).  
 
 
Figure 4.6 Endothelin receptor antagonists BQ-123 and BQ-788 have no effect 
on baseline BP 
Vehicle and two doses of antagonists were infused intravenously into C57Bl/6JCrl 
mice over a 25 minute period. (A and C) Systolic and (B and D) diastolic blood pressure 
was recorded during infusion of (A and B) ETRA antagonist BQ-123 and (C and D) 
ETRB antagonist BQ-788. Data are mean±SEM from baseline and were analysed by 
two-way ANOVA with the P value given that of the drug treatment, n=4-7. 
 
At 1 mg/kg, BQ-123 did not diminish the pressor response to AZ’5538 but the 
higher dose of 2 mg/kg of BQ-123 significantly blunted the blood pressure 
increase (Figure 4.7 (A) and (B), BQ-123 treatment P=0.044, time P<0.0001 
and interaction P=0.988). Blockade of ETRB using BQ-7-88a had no effect on 
the pressor response to AZ’5538, (Figure 4.7 (C) and (D)). 
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Figure 4.7 Effect of specific endothelin receptor antagonists BQ-123 and BQ-
788 on GPR81 mediated blood pressure changes 
Vehicle and two doses of (A and B) ETRA antagonist BQ-123 and (C and D) ETRB 
antagonist BQ-788 were infused intravenously into C57Bl/6JCrl mice over a 25 minute 
period prior to being infused alongside AZ’5538 for 15 minutes at 1 µmol/kg/min. 
Antagonists were compared to vehicle. (A and C) Systolic and (B and D) diastolic blood 
pressure were recorded. All data are mean±SEM from baseline, n=4-7, analysed by 
two-way ANOVA with Tukey’s multiple comparisons test where the P value given is 
that of antagonist treatment. 
 
Multiple comparison statistics show a difference between vehicle and BQ-123 
2 mg/kg in DBP and a trend towards a difference in SBP while no differences 
were seen between vehicle and BQ-123 at a lower dose or BQ-788 (Table 
4.2). 
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Table 4.2 Two-way ANOVA multiple comparison statistics for specific 
endothelin receptor antagonist pre-treatment 
Data for ETRA specific antagonist BQ-123 and ETRB antagonist BQ-788 were 
analysed by two-way ANOVA with Tukey’s multiple comparisons test. P values given 
for main effect of BQ-123 or BQ-788 pre-treatment compared to vehicle. Significant 
values given in red. n=4-7. 
  
Vehicle vs 
1mg/kg
Vehicle vs 
2mg/kg
BQ-123
SBP 0.832 0.064
DBP 0.922 0.038
BQ-788
SBP 0.944 0.970
DBP 0.666 0.994
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4.3 Discussion 
 GPR81 and ET-1 expression  
In this chapter, it was found that activation of GPR81 with AZ’5538 for 15 
minutes in mice caused an increase in plasma ET-1 with no change in the 
tissue protein expression. This suggests release of stored ET-1 into the 
circulation rather than de novo synthesis and processing of pre-pro endothelin 
due to the short 15 minute time course of the experiments.  
 
Mature ET-1 (as well as the precursor big ET-1) is held in storage granules 
within endothelial cells, known as Weibel-Palade bodies150. These structures 
release their contents in response to either chemical or mechanical stimulus 
which cause release of the contents, including ET-1, or degranulation and 
breakdown of the Weibel-Palade bodies where they fuse with the 
membrane102,151. This is part of the regulated stimulated pathway for ET-1 
release102. For example a cold pressor test in healthy human forearms 
increases plasma ET-1 within 2 minutes152, a time course which is much too 
fast for production of new ET-1. Mechanical stretch in vitro on endothelial cells 
also showed degranulation of the storage granules and ET-1 release153. In 
terms of signal transduction pathways it has been shown that increasing 
intracellular calcium concentration or activating protein kinase C in human 
endothelial cells releases ET-1154,155 which presents the possibility that 
unknown pathways may mediate this response, for example GPR81 
activation. My data did not confirm this pathway of release but the 
measurement of a marker of Weibel-Palade bodies, for example P-selectin102, 
would, in future studies, help to determine if this is indeed the source of ET-1. 
If the release of ET-1 is due to degranulation of these structures, then an 
increase in other components of the granules will also be seen, therefore an 
increase in both ET-1 and von Willebrand factor would show breakdown of 
Weibel-Palade bodies156,157. 
 
In the kidney samples, a decrease in both ET-1 and ETRB gene expression 
was seen. This could potentially suggest negative feedback into the endothelin 
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system with an increase in circulating levels. ETRB decreasing could also be 
to prevent vasodilation caused by this receptor, encouraging activation of 
ETRA. Nevertheless, the time course of this experiment is 15 minutes, making 
it unlikely that agonist treatment induced changes in gene expression. It is 
therefore possible that this is not a true effect of GPR81 activation. It is 
currently unknown whether GPR81 activation long term alters the transcription 
of the genes associated with the endothelin system.  
 
There are similarities in the effects seen with ET-1 and AZ’5538 infusion in 
vivo including increased blood pressure and reduced renal blood flow. The role 
of ET-1 in direct vasoconstriction is well known however studies have shown 
that exogenous ET-1 in many animal models including dogs, rabbits and rats 
causes a reduction in renal blood flow and glomerular filtration rate123–125, 
similar to the findings here. ET-1 vasoconstricts both afferent and efferent 
arterioles158,159, the suggested location of expression of Gpr81 mRNA in the 
kidney cortex.  
 
Since GPR81 is a Gi coupled receptor, the receptor exerts it’s effects by 
lowering intracellular levels of cAMP, altering downstream pathways. 
Importantly, it has been shown that cAMP can influence vasomotor tone 
indirectly, via the endothelin pathway. An inverse relationship between cellular 
cAMP and ET-1 production is established160,161 and agents that inhibit cAMP 
in vascular smooth muscle augment ET-1 production162. These studies in 
human primary VSMCs showed decreases in both ET-1 peptide and pre-
proendothelin mRNA expression in cells treated with agents which increase 
cAMP concentration (Ro-20-1724, cicaprost and forskolin) over a 24 or 48 hour 
period160,161.  
 
Although plausible, the literature doesn’t provide any direct evidence 
connecting lactate (or GPR81) and ET-1, beyond the pharmacological studies 
of Wallenius et al.65 and those outlined here. However, there are studies which 
help to explain this indirectly. A study by Barrett-O’Keefe et al. performed in 8 
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adult male humans reported both the concentration of plasma lactate and ET-
1 during exercise163. While no connection between these variables was made 
in the paper, I have plotted the data and identified a positive correlation (Figure 
4.8). This suggests a system where GPR81 may be the primary sensing 
system, responding to locally increased extracellular lactate to stimulate ET-1 
release and constrain vasodilation during exercise to optimise muscle 
perfusion while protecting MABP. 
 
 
Figure 4.8 Correlation between plasma ET-1 and lactate release during exercise 
Graph plotted from data from Barrett-O’Keefe et al.163. Human subjects underwent 
increasing levels of exercise (knee extensor paradigm). ET-1 or lactate release was 
calculated from femoral venous and arterial plasma samples by ELISA and blood gas 
analysis, respectively. Net release was calculated using the following equation: 
(venous concentration − arterial concentration) × {leg blood flow × [101 − 
(haematocrit/100)]}. Data are mean±SEM, n=8, linear regression shown which has a 
significant correlation, P=0.038. 
 
Similarly, hypoxia, which also increases extracellular and circulating lactate 
levels, has been associated with ET-1 increases. This has been shown both 
in vitro in bovine endothelial cells119 as well as ex vivo. In rat mesenteric 
arteries, hypoxia resulted in increased ET-1 release120. The same was seen in 
porcine coronary arteries121 and it was also suggested that ET-1 counteracts 
the hypoxia induced vasodilation with local vasoconstriction. They suggest that 
the hypoxic vasodilation in the coronary system is essential in states of low 
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oxygen but ET-1 may counteract this to maintain normal blood pressure 
throughout other organ systems to overall sustain MABP. 
 
 Endothelin receptors involvement in GPR81 activation 
ET-1 as a ligand is able to exhibit opposing vascular effects depending on the 
receptor type and localisation of the receptor which it activates (Figure 1.6). 
Here it was shown that the pressor effect of AZ’5538 was partially prevented 
using a pre-treatment of a mixed endothelin receptor antagonist Bosentan. A 
more substantial effect was seen with the lower dose of Bosentan in 
comparison to the higher. This can be explained by the increased level of 
ETRB blockade with the higher dose, opposing the ETRA blockade. The 
AZ’5538 blood pressure increase was fully prevented by pre-treatment with an 
ETRA antagonist, BQ-123 with no effects of BQ-788 (ETRB antagonist). BQ-
788 and the vehicle (2.3/4.6% DMSO) resulted in a smaller increase in BP with 
AZ’5538 in comparison to AZ’5538 alone or with saline as a vehicle pre-
treatment. This may be due to the DMSO component, especially when used 
at the higher concentration of 4.6%. It was shown that DMSO vehicle alone 
did not cause a direct effect on BP however it did blunt the response to 
AZ’5538 compared to saline somewhat. It has been previously shown that 
DMSO can have effects on blood pressure, a study in dogs showed a transient 
increase in both systolic and diastolic blood pressure with IV infusion164 and 
this is a caveat for the interpretation of my data.164. It is, however, clear from 
the BQ-123 study that the GPR81 effect is ETRA-dependent. This is supported 
by a study also using BQ-123 but in canine kidneys. It was shown that 
reductions in renal blood flow and glomerular filtration caused by ET-1 were 
abolished with ETRA antagonism while a ETRB antagonist had no effect on 
these parameters19. The ETRB antagonist, Sarafotoxin 6c, did increase urine 
flow and sodium excretion in these animals however this is not an effect seen 
with GPR81 activation, in fact, I have shown a decrease in urine flow and no 
change in sodium excretion.  
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Expression of the two endothelin receptor types are very different and ETRA 
tends to be localised to where I or others have also found Gpr81 expression. 
While ETRA is expressed on smooth muscle cells where they cause a cascade 
leading to vasoconstriction, ETRB is predominately located on endothelial 
cells causing vasodilation101. The tissue type distribution of ETRA is also 
different to ETRB and supports the findings presented in this chapter. ETRA is 
much more highly expressed in cardiovascular tissue, including the 
vasculature, while ETRB is at higher levels in the brain165. Even though at 
lower levels than ETRB in the brain, ETRA is enriched in pial arteries166 which 
is of particular interest as Gpr81 mRNA expression has been localised here42. 
In the medulla of the kidney, ETRA is located on pericyte cells along the vasa 
recta which provides the medullary microcirculation and vasoconstriction here 
has been shown to be ETRA dependant167. From the in situ hybridisation 
studies, high levels of expression were also seen here for Gpr81. 
 
I propose a mechanism by which increased local concentrations of 
extracellular lactate activates GPR81 on smooth muscle cells, lowering cAMP 
and causing activation of ETRA and causing vasoconstriction.  
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 Summary of chapter findings 
− Activation of GPR81 with AZ’5538 increases circulating ET-1 but not 
tissue protein levels. 
− The GPR81 pressor response is ETRA mediated and not ETRB. 
− A longer study is needed to determine changes in gene expression. 
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Chapter 5 - GPR81 mediated 
changes in vascular tone and 
function by wire myography 
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5.1 Introduction 
In previous chapters I have presented in vivo data indicating GPR81-specific 
effects on blood pressure and renal blood flow. Given the rapidity of onset and 
the localisation of the receptor in the vascular smooth muscle, I hypothesised 
that systemic vasoconstriction occurred due to a direct contractile effect of 
GPR81 activation on smooth muscle of both resistance and conduit arteries 
through the vasculature. I address this hypothesis in the current chapter, using 
wire myography to measure vascular contractility in isolated aortae, 
mesenteric and renal arteries.  
 
Wire myography is a technique that allows the assessment of known 
vasoactive drugs and compounds with unknown vasoactive roles, such as 
GPR81 agonist AZ’5538. It also enables the comparison between treatments, 
genotype and artery types to help understand mechanisms underlying 
changes in vascular tone.  
 
In this chapter, I aim to use wire myography to, firstly, evaluate the potential 
vasoactive effects of AZ’5538 on aortae, mesenteric and renal arteries from 
wildtype mouse arteries by incubating vessels with the drug and carrying out 
dose response protocols with known vasoactive drugs. Secondly, I will 
determine if these effects are blocked by ETRA antagonism, as the in vivo 
changes are by prior incubation with BQ-123. Next I will characterise 
differences between wildtype and Gpr81-null mouse vasoreactivity to 
compounds of known vasoconstrictive or dilatory function (for example 
phenylephrine, acetylcholine and sodium nitroprusside). And finally, I plan to 
assess if any vascular changes seen with AZ’5538 treatment ex vivo are 
specific to GPR81 using arteries from the Gpr81-null mouse and wildtype 
littermates.  
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5.2 Results 
 GPR81 activation has direct vascular effects ex vivo 
The ability of vessels to vasoconstrict in the presence of high potassium before 
and after incubation with the GPR81 agonist, AZ’5538, was assessed in 
C57BL/6JCrl mouse aortae and mesenteric arteries (Figure 5.1). A value of 
0% shows no change vasoconstrictive ability from the beginning to the end of 
the experiment. In both aortae and mesenteric arteries at concentrations 
above 31.3 µM of AZ’5538 the viability of the vessels went below zero, 
suggesting damage to the vessels from the incubation. Therefore, 30 µM was 
taken forward as the highest concentration of AZ’5538 which did not affect the 
reactivity of vessels.  
 
Figure 5.1 Concentration test of AZ’5538 on isolated aortae and mesenteric 
arteries 
Percentage change in (A) aortae and (B) mesenteric arteries response to KPSS 
(125mM KCl) before and after addition of 5% mannitol vehicle or AZ’5538 to the wire 
myograph for 15minutes (n=2-5). Data was not analysed for statistical significance due 
to low n numbers. 
 
Aortae, mesenteric and renal arteries were all selected for wire myography. 
Incubation of aortae and mesenteric arteries from basal tension with AZ’5538 
or vehicle showed no differences (Figure 5.2(A) ANOVA drug treatment 
P=0.668, time P=0.056 and interaction P=0.917 and (B) drug treatment 
P=0.268, time P=0.262 and interaction P=0.126, respectively). Renal arteries 
showed a time-dependent increase in vasoconstriction with AZ’5538 treatment 
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which plateaued at ~10 minutes (Figure 5.2(C) ANOVA drug treatment 
P=0.005, time P=0.001 and interaction P<0.0001).  
 
 
Figure 5.2 AZ’5538 causes vasoconstriction in the renal artery but not aorta or 
mesenteric arteries 
Sections of (A) aortae, (B) mesenteric arteries and (C) renal arteries were incubated 
for 15 minutes with 30 µM AZ’5538 (black squares) or 5% mannitol vehicle of the same 
volume (grey circles) (n=8 for all). Data is presented as a percentage of the response 
to KPSS and was analysed by two-way ANOVA. 
 
All vessels which were subjected to AZ’5538 or vehicle incubation then went 
through a series of dose response experiments with known vasoconstrictors 
and dilators. The overall vessel responses to PE were decreased in 
mesenteric and renal arteries (Figure 5.3(C) and (E)) as well as their maximal 
response to this drug (Table 5.1) while there were no changes in the aorta 
(Figure 5.3(A) and Table 5.1). The endothelium-dependent vasodilator ACH 
was attenuated with AZ’5538 treatment with ANOVA drug treatment statistics 
being significant for all vessel types (Figure 5.4(A), (C) and (E)). The IC50 was 
also decreased for all vessel types (Table 5.1 Changes in vascular reactivity 
in vessels treated with AZ’5538). The aorta showed no change in maximal 
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response, mesenteric arteries showed a decreased maximal response while 
renal arteries showed an increase (Table 5.1). There were no differences in 
responses to SNP (an endothelium-independent nitric oxide donor) for any of 
the vessel types (Figure 5.4(B), (D) and (F) and Table 5.1). With the range of 
ET-1 concentrations used it was not possible to fit a full non-linear regression 
and therefore EC50 and Emax values could not be calculated or analysed. There 
were no differences between two-way ANOVA results from ET-1 on any vessel 
type (Figure 5.3(B), (D) and (F)). 
 
 
Figure 5.3 AZ’5538 alters vascular response to vasoconstrictors ex vivo 
Aorta (A and B), second order mesenteric arteries (C and D) and renal arteries (E and 
F) were incubated with vehicle (grey circles) or 30 µM AZ’5538 (black squares) before 
being subjected to increasing concentrations of vasoconstrictors PE (A, C, E), and ET-
1 (B, D, F) (n=8 for all). Data shown as a percentage force of the maximum response 
to KPSS. All curves shown as non-linear regression and analysed by two-way ANOVA 
where the P value given is the effect of AZ’5538 versus vehicle. 
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Figure 5.4 AZ’5538 alters vascular response to vasodilators ex vivo 
Aorta (A and B), second order mesenteric arteries (C and D) and renal arteries (E and 
F) were incubated with vehicle (grey circles) or 30 µM AZ’5538 (black squares) before 
being subjected to increasing concentrations of ACH (A, C, E) and SNP (B, D, F) (n=8 
for all). Data shown as a percentage to their individual vasoconstriction to half maximal 
with PE prior to dose response. All curves shown as non-linear regression and 
analysed by two-way ANOVA where the P value given is the effect of AZ’5538 versus 
vehicle. 
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To confirm that the dose of AZ’5538 followed by four drug dose response 
experiments did not affect vessel viability, the percentage change in KPSS 
response was analysed and no differences were seen between AZ’5538 and 
vehicle in any vessel (Figure 5.5). 
 
 
Figure 5.5 AZ’5538 does not alter the ability of vessels to vasoconstrict by KCl 
depolarisation 
(A) Aortae, (B) mesenteric arteries and (C) renal arteries were depolarised with 125 
mM KCl at the beginning and end of the experiment to determine viability of the vessels 
where vehicle treated (grey circles) and AZ’5538 treated (black squares) were 
compared (n=8 for all). Data was analysed by t-test. 
 
Preconstriction of vessels can alter their response to vasoactive compounds. 
An example of this ANG II where preconstriction of some vessels is required 
to elicit a vasoconstrictive response168, as shown in Figure 5.6. For this reason, 
all three vessel types underwent dose-response protocols with increasing 
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doses of AZ’5538 from basal tension in normal PSS or with an increased 
potassium concentration (Figure 5.7). As with a single incubation of the drug, 
aortae showed no difference in vasoactivity from basal (Figure 5.7(A) ANOVA 
preconstriction P=0.453, [AZ’5538] P=0.232, interaction P=0.170). At basal 
conditions there was no effect of AZ’5538 on mesenteric vessels however with 
preconstriction there was a dose-dependent decrease in tension (Figure 
5.7(B) preconstriction P=0.272, [AZ’5538] P=0.033, interaction P<0.0001). For 
renal arteries there is a dose-dependent increase in vasoconstriction at basal 
tone (Figure 5.7(C)). Conversely, preconstriction of renal arteries changed 
AZ’5538 from being vasoconstrictive to vasodilatory (ANOVA preconstriction 
P=0.007, [AZ’5538] P=0.387 and interaction P<0.0001). Although these are 
opposing effects on the vessel, they start to alter tone at the same point 
(around 3µM). 
 
 
Figure 5.6 Vasoconstriction of aortae with and without prior preconstriction with 
KCl 
Aortae (n=8 per group) were incubated with normal PSS (4.7 mM K+, grey circles) or 
a higher potassium salt solution (25 mM K+, black squares). Vessels were then 
subjected to increasing doses of ANG II. Data shown as non-linear regression curves 
as a percentage to maximum KPSS response and was analysed by two-way ANOVA 
with the statistical significance given on the figure as the difference between the two 
potassium treatment groups.  
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Figure 5.7 Preconstriction of vessels with KCl alters AZ’5538 mediated 
vasoconstriction 
(A) Aortae, (B) mesenteric arteries and (C) renal arteries were incubated in normal 
PSS (4.7 mM K+, grey circles) or increased KCl PSS (25 mM K+, black squares) (n=8 
for aorta and mesenteric, n=7 for renal arteries) prior to increasing doses of AZ’5538. 
Data is shown as non-linear regression curves and was analysed by two-way ANOVA 
with the statistics given between KCl concentration groups.  
 
 Blockade of ETRA does not prevent GPR81 mediated 
vasoconstriction 
With the aim to inhibit the vasoconstriction caused by AZ’5538 on renal 
arteries, a range of concentrations of BQ-123 were analysed ex vivo in the wire 
myography set up. None of the doses of BQ-123 had any effect on basal 
vascular tone of renal arteries with no change in tone larger than 2% of KPSS 
response (Figure 5.8(A)). There was a significant difference in the different 
drug doses by two-way ANOVA (BQ-123 doses P=0.050, time P=0.125, 
interaction P=0.737) however this is probably due to the small differences seen 
between doses. No significant differences were seen in the viability of the 
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vessels before and after BQ-123 treatment (Figure 5.8(B)) however there was 
a slight decrease as the doses increased (mean vehicle 0.03%, BQ-123 1 µM 
-3.96%, 3 µM -5.12%, and 10 µM -9.15%). All doses were able to inhibit the 
vasoconstrictive response of ET-1 on renal arteries (two-way ANOVA 
comparison at 300 µM ET-1 between vehicle and 1 µM BQ-123 P=0.0002, 3 
µm BQ-123 P=0.0003, and 10 µM BQ-123 P<0.0001). The lowest dose of BQ-
123 (1 µM) was taken forward due to this having the smallest effect on KPSS 
response. 
 
 
Figure 5.8 Ex vivo blockade of ETRA using BQ-123 
Renal arteries of C57BL/6JCrl mice treated with vehicle or BQ-123 at varying 
concentrations for 30 minutes (n=4 for all groups). (A) response of vessels to BQ-123 
incubation given as a percentage of response to KPSS. (B) percentage change of 
vessel vasoconstriction with KPSS before and after BQ-123 treatment compared 
using one-way ANOVA with each BQ-123 concentration compared to vehicle. (C) 
renal arteries treated with increasing concentrations of ET-1 after BQ-123 incubation. 
Compared using two-way ANOVA with multiple comparisons where each dose of ET-
1 saw vehicle compared to all doses of BQ-123. Data presented as a percentage of 
response to KPSS. 
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Renal arteries were incubated with BQ-123 or vehicle before the addition of 
AZ’5538 or vehicle to determine if this could inhibit the vasoconstrictive 
response. All vessels treated with AZ’5538 showed a time-dependant increase 
in vasoconstriction which plateaued at around 10 minutes (Figure 5.9, 
P<0.0001 for both groups), as seen in Figure 5.2(C).The group treated with 
BQ-123 prior to AZ’5538 showed an attenuated response to the drug 
(P=0.017) but did still cause vasoconstriction in comparison to vehicle alone.  
 
Figure 5.9 Blocking ETRA ex vivo does not prevent AZ’5538 induced 
vasoconstriction 
Renal arteries incubated with vehicle (grey and black lines) or 1 µM BQ-123 (blue lines) 
for 30 minutes followed by 30 µM AZ’5538 (black and blue lines, n=15 and 8 
respectively) or vehicle (grey lines, n=8) for 15 minutes. Data presented as a 
percentage of the response to 125 mM KCl and analysed by two-way ANOVA mixed 
effect analysis with Tukeys multiple comparisons test.  
 
 Differences in vascular tone between Gpr81 null and WT 
mice 
Differences between mesenteric and renal arteries from mice lacking GPR81 
expression and their WT littermates were assessed to determine the vascular 
role of GPR81. As anticipated, the force of mesenteric contraction to high 
potassium was greater than renal arteries (Figure 5.10). No differences were 
seen between genotypes for either artery type (Figure 5.10(A) WT 5.45±2.31 
mN KO 4.72±3.35 mN (B) WT 2.81±1.78 mN KO 2.85±1.56 mN, for mesenteric 
and renal respectively).  
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Figure 5.10 Gpr81-/- and Gpr81+/+ mice have no differences in depolarisation 
response 
(A) Mesenteric (n=12) and (B) renal arteries (n=11-12) from Gpr81 null (red squares) 
and WT (black circles) show no differences in response to 125 mM KCl containing 
KPSS. Data analysed by unpaired t-test. 
 
Known vasoactive drugs were analysed to assess any potential differences 
between genotypes. No differences were seen between Gpr81+/+ and Gpr81-/- 
mesenteric and renal arteries to vasoconstrictors PE or ET-1 (Figure 5.11(A), 
(B), (G), (H) and Table 5.2). As previously, a full dose-response curve for ET-
1 was not reached therefore non-linear regression data was not possible to 
calculate. There were also no differences between genotypes in renal arteries 
treated with SNP (Figure 5.11(F) and Table 5.2) however mesenteric arteries 
from Gpr81-/- showed a leftward shift in the curve, increasing the IC50 and 
suggesting increased potency (Table 5.2, WT IC50 6.76±0.26 -log[M], KO 
7.91±0.15 -log[M], P=0.005). For both vessel types, differences were seen in 
the responses to the endothelium-dependent vasodilator ACH. Renal arteries 
exhibited a genotype difference in two-way ANOVA statistics (Figure 5.11(D) 
P=0.046) as well as an increased Imax value in the Gpr81-/- mice, implying an 
inability of these vessels to completely vasodilate with this drug (Table 5.2, WT 
Imax 16.61±4.72%, KO 29.98±3.65, P=0.028). Conversely, mesenteric arteries 
from Gpr81-/- mice showed an increased IC50 for ACH compared to WT 
meaning they dilated to a lower concentration of the vasodilator while showing 
no difference in Imax (Table 5.2, WT IC50 7.17±0.16 -log[M], KO 7.73±0.17 -
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log[M], P=0.046). Mesenteric arteries from wildtype mice incubated with 30 µM 
AZ’5538 from basal tone showed no affect (Figure 5.11(I)), consistent with 
Figure 4.2 (B). These arteries from Gpr81-/- showed no difference and no 
vasoconstriction was seen. Renal arteries also showed no difference between 
genotypes when treated with AZ’5538 (Figure 5.11(J)). Both renal arteries from 
wildtype and Gpr81-/- mice gradually vasoconstricted over time, plateauing at 
around 11 minutes and with a maximum contraction of 22.25±16.40% of KPSS 
response for WT and 22.23±12.78% for Gpr81 null mice.  
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Figure 5.11 Differences in response between Gpr81-/- and Gpr81+/+ mouse 
vessels to known pharmacological vasoconstrictors and dilators 
Mesenteric arteries (A,C,E,G,I) and renal arteries (B,D,F,H,J) from Gpr81 WT (black 
circles and KO (red squares) mice subjected to increasing concentrations of PE (A,B), 
ACH (C,D), SNP (E,F), ET-1 (G,H). For these drugs, curves shown are non-linear 
regressions. Vessels were also incubated with 30 µM AZ’5538 for 15 minutes (I, J). 
n=5-6. PE, ET-1 and AZ’5538 are displayed as a percentage force of the maximum 
response to KPSS while vasodilators ACH and SNP as a percentage to their individual 
vasoconstriction to half maximal with PE. All data was analysed by two-way ANOVA 
where the P value given is the effect of the genotype. 
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To determine if differences between vessels treated with AZ’5538 or vehicle 
(Figure 5.3, Figure 5.4 and Table 5.1) were GPR81-specific effects, 
mesenteric and renal arteries were from both Gpr81-/- and wildtype littermates 
were all incubated with the agonist prior to dose response curves. Although 
differences were seen in C57BL/6JCrl mouse vessels to PE with and without 
AZ’5538 treatment (Figure 5.3 (B) and (C)), there were no differences here 
between genotypes (Figure 5.12 (A) and (B) and Table 5.3). Previously, there 
were differences in mesenteric and renal arteries incubated with AZ’5538 in 
their response to ACH. The IC50, Imax and ANOVA drug treatment statistic were 
all significantly different for both vessel types (Figure 5.4(E) and (F) and Table 
5.1) however when this was examined in animals lacking the Gpr81 gene, the 
only difference seen was the Imax for mesenteric vessels (Figure 5.12 (C) and 
(D) and Table 5.3). There was a genotype difference in the Gpr81-/- and 
Gpr81+/+ mouse mesenteric artery response to SNP (Figure 5.12 (E)) as well 
as a reduced IC50 value (Table 5.3, WT IC50 7.36±0.10 -log[M], KO 7.75±0.07 
-log[M], P=0.006) whereas no difference was seen in wildtype animals 
between AZ’5538 and vehicle (Figure 5.4(H) and (I)). No differences were 
seen with ET-1 treatment in either group (Figure 5.12(G) and (H)).  
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Figure 5.12 Differences in response between Gpr81-/- and Gpr81+/+ mouse 
vessels to known pharmacological vasoconstrictors and dilators after AZ’5538 
incubation 
Mesenteric arteries (A, C, E, G) and renal arteries (B, D, F, H) from Gpr81 WT (black 
circles and KO (red squares) mice were all treated with GPR81 agonist AZ’5538 (30 
µM for 15 minutes). All vessels were then subjected to increasing concentrations of PE 
(A, B), ACH (C, D), SNP (E, F), ET-1 (G, H). For these drugs, curves shown are non-
linear regressions. n=6 for all. PE and ET-1 are displayed as a percentage force of the 
maximum response to KPSS while vasodilators ACH and SNP as a percentage to 
their individual vasoconstriction to half maximal with PE. All data was analysed by two-
way ANOVA where the P value given is the effect of the genotype. 
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With the aim to identify differences between the WT and Gpr81-/- mouse renal 
artery vasoconstriction by AZ’5538, increasing doses of the GPR81 agonist 
were applied to the arteries. Although there were no differences in the overall 
genotype effect when analysing by two-way ANOVA, there was a significant 
different in the interaction of the dose response curves (Figure 5.12, ANOVA 
genotype P=0.263, concentration P<0.0001 and interaction P=0.008). There 
was a trend towards a difference in EC50 values with the KO renal arteries 
requiring a higher dose of AZ’5538 to reach the same vasoconstriction as WT 
arteries (Table 5.4). Due to large variation in the contraction at the highest 
dose of AZ’5538 (30 µM), there is also no significant difference in Emax between 
genotypes. To get a full dose response curve for these vessels, a higher dose 
of AZ’5538 is required however, as shown in Figure 5.1, doses above 30 µM 
effect the viability of vessels and any results seen may actually be due to 
damage of the vessels.  
 
 
Figure 5.13 Vasoconstriction in renal arteries from Gpr81-/- and Gpr81+/+ mice 
caused by AZ’5538 
Renal arteries from Gpr81 WT and null mice treated with increasing concentrations of 
AZ’5538 (n=10-11 from 6 mice). Data plotted as a percentage of the maximum 
constriction from 125 mM KCl and a non-linear regression formed. All data was 
analysed by two-way ANOVA where the P value given is the effect of the genotype. 
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5.3 Discussion 
In this chapter, I assessed the effect of GPR81 activation and genetic deletion 
on ex vivo arterial reactivity. The main findings were; a) AZ’5538 induced 
contraction which was partly dependent on ETRA, b) genetic deletion of Gpr81 
altered the response to ACH, renal arteries had a lower maximal vasodilation 
while mesenteric arteries responded quicker to lower doses, c) importantly, the 
majority of direct vascular actions of AZ’5538 appear to be off target since they 
were also observed in Gpr81 null mice.  
 
 GPR81 mediated arterial reactivity 
The literature on lactate (the endogenous ligand of GPR81) causing direct 
vasoactive effects is brief however there are some suggestions of a vasoactive 
role for lactate and GPR81 ex vivo, which I aimed to explore. On aortic 
segments from basal tone, L-lactate (10 nM - 1 mM) had no effect169. 
Physiological plasma levels of lactate around 0.5-2mM, rising to 10-30mM 
during intense exercise or prolonged hypoxia30,31,85 with the EC50 of the 
receptor to lactate being ~5 mM31. It could be that the concentration of lactate 
used in this study was not high enough to elicit a response however this is 
consistent with our findings in aortae with AZ’5538 as no effect was seen. 
Interestingly, a study using isolated rat mesenteric arteries which were 
preconstricted showed relaxation with increasing concentrations of L-lactate170 
which was seen in both renal and mesenteric arteries with AZ’5538, although 
this was not assessed in the Gpr81-/- animals to confirm specificity170. This 
study by McKinnon et al., used a much higher concentration of lactate going 
up to 50 mM and showed significant relaxation from 6 mM. These vessels were 
preconstricted with noradrenaline prior to lactate administration however they 
saw no response to lactate if the vessels were preconstricted with 45 mM K+. 
Here, vessels were all preconstricted with a lower concentration of K+ (25 mM) 
and relaxation was seen with AZ’5538 treatment. It could be that the tension 
was too high in their study to allow lactate to cause relaxation or again this 
could be a non GPR81-mediated response which was seen with AZ’5538. The 
relaxation effect they saw here was not pH, endothelium or nitric oxide 
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dependant which supports our data of GPR81 being expressed in smooth 
muscle cells and this being a direct response. It is well documented that 
plasma lactate levels increase in states of hypoxia85 and there is literature 
looking at the effect of oxygen deprivation on vascular tone ex vivo and in vivo 
but none of which have made the connection with lactate. In general, hypoxia 
causes vasoconstriction of the pulmonary arteries and vasodilation 
systemically171 which is caused by responses in both endothelial and smooth 
muscle cells172. Ex vivo, hypoxia (partial oxygen pressure (PO2) <5 mmHg) 
caused decreased vessel tone in rat mesenteric arteries after preconstriction 
with high K+173, the same way AZ’5538 did in both mouse mesenteric and renal 
arteries171. In this study by Otter et al., the decrease in tone was coupled with 
decreased pH which could imply an increase in lactate due to hypoxic 
conditions.  
 
As discussed in previous chapters, in vitro and in vivo it is known that 
circumstances where lactate levels are high (for example hypoxia or intense 
exercise), ET-1 levels are also increased119,163. Since a relationship was 
determined between GPR81 and ETRA, the aim was to prevent AZ’5538 
mediated vasoconstriction by blocking the ETRA as it was possible to inhibit 
the blood pressure response seen in vivo. Using BQ-123 as in the in vivo 
studies, the effect of AZ’5538 on renal arteries was dampened by not 
prevented. As vasoconstriction was still seen with AZ’5538 in the Gpr81-/- 
mouse, this may be why there is still an increase in tension even though ETRA 
is blocked. 
 
Although it was not possible to determine the underlying mechanism of 
GPR81-mediated vasoconstriction using wire myography, there is a wealth of 
literature to support GPR81, ET-1 and vasoconstriction. It is well established 
in adipocytes that GPR81 functions to inhibit lipolysis through a Gi coupled 
pathway, lowering cAMP levels which downstream decreases PKA activity31. I 
have not yet shown this in vessels, but other studies support the concept. For 
example, in preconstricted mesenteric arteries exhibited vasodilation with 
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lactate administration170. This effect was blocked in the presence of a cAMP 
analogue (Rp stereoisomer of adenosine-3',5'-cyclic monophosphothioate) 
suggesting that the vascular effects of lactate are mediated through cAMP. A 
similar mechanism has been suggested ex vivo in mouse femoral arteries 
where increased cAMP using the phosphodiesterase inhibitor Cilostazol 
prevented vasoconstriction by ET-1162, implying a connection between Gi 
pathway inactivation and ET-1. This study and others used in vitro models with 
smooth muscle cells to determine that ET-1 dependent calcium influx is 
inhibited by preventing the inactivation of cAMP which may be the cause of 
this smooth muscle ET-1 vasoconstriction147,162. Adenosine also functions in a 
Gi coupled manner and Hansen et al. has shown in isolated perfused mouse 
afferent arterioles of the kidney that lowering cAMP therefore decreasing PKA 
activity causes vasoconstriction145. This is of particularly interest as I have 
previously suggested GPR81 expression in the smooth muscle cells of afferent 
and efferent arterioles of the kidney where it may initiate a vasoactive response 
causing increase blood pressure and decreased renal blood flow. Finally, ex 
vivo studies using hypoxia have shown increased ET-1 and changes in 
vascular function. In rat mesenteric arteries, hypoxia increased ET-1 release 
causing vasoconstriction and suggesting an important role in local vascular 
tone in states of hypoxia120. In the same way, in porcine coronary arteries, it is 
suggested that the systemic vascular response to hypoxia of vasodilation is 
counteracted by the release of ET-1 causing vasoconstriction121. Although the 
underlying connection and mechanism between hypoxia, GPR81, ET-1 and 
vascular tone have not been fully elucidated it would seem there is a 
connection which the literature supports, and which needs to be further 
investigated. 
 
 Effect of Gpr81 genetic deletion and vascular function  
Many differences were seen between vessels from wildtype C57BL/6JCrl 
animals treated with AZ’5538 or vehicle, in particular in the responses to PE 
and ACH. To assess if these were due to GPR81 activation, incubation with 
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AZ’5538 was carried out in both genotypes. These differences were no longer 
presented suggesting this was an off-target effect of the agonist. 
 
There were differences in vascular responses between arteries from Gpr81+/+ 
and Gpr81-/- mice. Specifically, renal arteries from Gpr81-/- mice showed a 
reduction in their ability to vasodilate in response to ACH which resulted in a 
decreased maximal vasodilation. Mesenteric arteries from KO animals showed 
a leftward shift in the dose response curve and an increased -logIC50 meaning 
they are able to vasodilate at lower concentrations of ACH. These opposing 
findings could suggest changes to the endothelial cell in response to the 
deletion of Gpr81. There was also a significant increase in the -logIC50 in KO 
animals to SNP however the data was very variable. If this is a true finding, it 
would be interesting to analyse other resistance vessels throughout the Gpr81-
/- mouse vasculature to assess if others have altered (either increased or 
decreased) ability to relax to a range of endothelium dependant and 
independent vasodilators. 
 
 Off target effects of AZ’5538 in wire myography 
In chapter 3 I showed that AZ’5538 causes a range of cardiovascular and renal 
effects when IV infused into mice in vivo. These effects were GPR81-specific 
as the AZ’5538 had no action in Gpr81-null mice. Conversely, in this chapter, 
vasoconstriction was seen only in renal arteries, but this effect was present in 
the Gpr81-/- mice also. In the well of the myograph, there are off-target GPR81 
independent mechanisms which are changing vascular tone by AZ’5538. 
There are still differences between genotypes, suggesting that some of the 
effect seen is GPR81 specific as there is an interaction difference between the 
dose response curves for the wildtype and knockout animals. An obvious 
cause for this change would be a pH change in the bath causing the change 
in vascular tone however the pH of the vehicle is always altered to that of the 
drug (around pH 5) and there was no effect of vehicle alone so that theory can 
be discounted.  
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AZ’5538 is a specific GPR81 drug created by AstraZeneca. The compound 
was designed and selected using a series of thorough in vitro and in vivo 
discovery steps to ensure specificity of the compound to GPR8165. These 
included high-throughput screening of forskolin-stimulated cAMP in GPR81 
transfected cells, inhibition of lipolysis experiments in primary human and rat 
adipocytes, pharmacokinetic evaluation and assessment of lipolysis inhibition 
in anesthetised rats. The off-target effects in wire myography are surprising 
when you consider the rigorous selection process by AstraZeneca along with 
our data on in vivo specificity of the drug. 
 
A way to assess the specificity of GPR81 mediated vasoconstriction could be 
the use of a different compound to activate the receptor. Other exogenous 
agonists for GPR81 do exist, these include 3-hydroxybenzoic acid (3-HBA) 
which targets both GPR81 and GPR109a while 3,5 dihydroxybenzoic acid 
(3,5-DHBA) is specific to GPR81174, 3-chloro-5- hydroxybenzoic acid (CHBA) 
has also been identified as a specific GPR8166. For all of these compounds, 
there is currently no literature on blood pressure or vasoreactivity of these 
compounds however they have been implicated in altering lipid profiles by 
receptor activation both in vivo and in vitro66,175. Assessment of new agonists 
would also require repeating the in vivo experiments to confirm that all agonists 
of GPR81 cause these hypertensive effects as well as ex vivo analysis using 
wire myography to determine if all GPR81 agonists have off target effects in 
this setting. 
 
The data suggests that there is something that differs in vivo in comparison to 
the well of myography to explain the effects in the knockout animals. This could 
potentially be caused by damage to the vessels endothelium when mounting 
the vessels, however, responses to ACH confirm this is not the case. An 
obvious element that is missing in the well of the myograph is the circulation. I 
have previously discussed the presence of GPR81 on immune cells176 and this 
could be the missing link between in vivo and ex vivo here. It is possible to 
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isolate immune cells and use them in the myograph and this would be an 
important experiment to carry out in the future.  
 
The literature and our data suggest that there is a role for GPR81 in direct 
vasoconstriction of vessels however more work needs to be done to 
understand the specific effects and the knockout mouse model will be useful 
in assessing specific GPR81 effects. 
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 Summary of chapter findings 
− AZ’5538 causes vasoconstriction in mouse renal arteries however this 
is not GPR81-specific. 
− BQ-123 does not completely block vasoconstriction caused by 
AZ’5538. 
− AZ’5538 also causes dose dependant vasodilation on mesenteric and 
renal arteries after preconstriction with K+ which is not confirmed to be 
GPR81 specific. 
− Gpr81-/- mice show opposing differences in ACH responses in different 
vessel types compared to wildtype. Mesenteric arteries respond at a 
lower dose while renal arteries have an impaired vasodilatation. 
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Chapter 6 - Discussion 
  
 115 
The major findings of my PhD are as follows: that GPR81 is expressed in the 
vasculature, including the renal vasculature, of the mouse; that activation of 
the receptor in vivo causes a GPR81 specific rapid increase in blood pressure; 
reduction in blood flow to the kidneys and glomerular filtration rate. I further 
demonstrated that the blood pressure increase caused by GPR81 activation is 
ETRA dependent and causes an increase of ET-1 in the circulation.  
 
6.1 Localisation of GPR81 
The majority of studies focus on  GPR81 expression in adipose tissue. The 
receptor is enriched here, and the effects of receptor activation are well 
defined. However, it is also present across a range of non-adipose tissues, 
with expression in the highly vascularised tissues of heart, skeletal muscle and 
kidney being ~10% of that in adipocytes30. My studies localised Gpr81 
expression in the mouse within the vascular smooth muscle of the aorta and 
renal arteries, the glomerular arterioles in the kidney cortex as well as within 
the medulla. To confirm smooth muscle localisation of the Gpr81 RNA, it would 
be necessary to colocalise this expression with known markers, e.g. α-smooth 
muscle actin. I also have preliminary data from the Denby group in our centre 
who used fluorescence-activated cell sorting (FACS) on CD-1 adult mouse 
whole kidneys. They separated cell populations with antibodies for PDGFRβ 
for pericytes and fibroblasts, CD31 for endothelial cells, F4/80 for 
macrophages and lotus tetragonolobus lectin for tubular kidney cells.  From 
the 4 cDNA samples made from each of these cell populations, I was able to 
perform qPCR for GPR81 and determine cell type expression in the healthy 
mice from their study. The results for this are shown in Figure 6.1. No Gpr81 
expression was found in the 4 tubular cell samples and only one for the F4/80-
positive macrophage group. The cell population with the highest Gpr81 
expression was the PDGFRβ-positive pericyte/fibroblast group. There was one 
sample with some expression in endothelial CD31-positive cells with close to 
zero in the others. This is consistent with previous observations that Gpr81 
reporter expression does not co-localise with endothelial cell markers in the 
cerebral vasculature42. However, a study published in September 2019, 
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described high levels of GPR81 in cultured immortalised human umbilical vein 
endothelial cells177. Unfortunately, primary arterial vascular smooth muscle 
cells were not a cell population which were included in the FACS study; 
therefore, it is not possible to compare the relative expression levels between 
these and PDGFRβ-positive cells177. 
 
 
Figure 6.1 Gpr81 expression in cell sorted kidney cells from wildtype healthy 
CD1 mice 
Four whole kidneys from healthy adult male CD-1 mice were sorted using 
fluorescence-activated cell sorting (FACS) flow cytometry to separate out pericytes 
and fibroblasts (PDGFRβ), endothelial cells (CD31), macrophages (F4/80) and tubular 
cells (lotus tetragonolobus lectin). qPCR was carried out using the UPL system with 
primers for Gpr81. Four samples for each cell type were assayed and only those with 
positive values are shown here. Data are mean±SEM. 
  
During the course of my PhD study, single-cell RNA sequencing has become 
more widely used and the sharing of large transcriptomic data more 
commonplace.  I was thus able to examine transcriptome data from mice to 
analyse the cell type specific expression of Gpr81 in a range of tissues. Firstly, 
the Kidney Cell Explorer178 is an excellent resource for renal researchers to 
investigate nephric and ureteric gene expression 
(https://cello.shinyapps.io/kidneycellexplorer/). This database shows that 
highest levels of Gpr81 (Hcar1) expression is grouped within the vascular and 
interstitial cell subsets. It is then possible to determine expression at specific 
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points through the nephron and collecting duct where Gpr81 is only found at 
the very end of the collecting duct, within the cells of the deep inner medullar 
and renal pelvis. In my in situ hybridisation studies there was extensive 
staining for Gpr81 within the medulla. Transcriptomic data confirming renal 
vascular expression is also promising as I found Gpr81 RNA in renal arteries 
as well as what appears to be the afferent and efferent arterioles adjacent to 
glomeruli in the cortex. A second single-cell sequencing data set which is 
readily available has investigated the cell type expression of genes from 
vascular tissue in the brain and lungs of adult transgenic reporter mice93. 
Previous studies have reported expression of GPR81 in the brain vasculature, 
specifically in the pial fibroblast-like cells that line blood vessels and in 
pericyte-like cells along intracerebral microvessels42. This is supported by this 
sequencing data where in the brain, Gpr81 expression is enriched in the 
fibroblast-like subsets as well as some expression seen in pericytes (Figure 
6.2 (A)). There is also a range of expression levels throughout the subsets of 
both vascular smooth muscle and endothelial cells. The expression profile for 
Gpr81 in the lung vasculature is quite different (Figure 6.2 (B)). A relatively 
high level of expression is found in pericyte cells with a broad expression 
profile throughout endothelial subsets. No expression is seen in the vascular 
smooth muscle cells of the lungs. This is of particular interest since in states 
of hypoxia, where an increase in lactate production is seen, pulmonary vessels 
tend to vasoconstrict while the peripheral vasculature shows opposing effects 
and  vasodilation is usually seen179. Overall, these data suggest that Gpr81 is 
present in both pericytes and endothelial cells, a finding which I did not 
replicate using RNAscope. As previously stated, co-localisation studies are 
essential for determining the cell specific location of Gpr81 in the kidney and 
renal vasculature. None of the data shown has analysed the expression of 
GPR81 at a protein level and therefore may not give a clear idea of the location 
of the active receptor. To achieve this, in depth antibody validation would need 
to be carried out to determine specificity prior to analysis. It is worth noting that 
my AZ collaborators indicated that commercially available antibodies were 
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unselective, providing positive results in tissue from KO mice (K Wallenius, 
personal communication).  
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Figure 6.2 Gpr81 expression from single-cell RNA sequencing of vascular and 
vessel-associated cell types of the mouse brain and lungs 
Figures adapted from the online database from the single-cell RNA sequencing 
experiment by He et al.93,180 http://betsholtzlab.org/VascularSingleCells/database.html. 
The brain and lungs from adult transgenic reporter mice were sorted into 15 and 17 
different cell types or subtypes respectively prior to sequencing. Average counts for 
Gpr81 are shown here for all cell subtypes analysed. 
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6.2 Mechanism of GPR81 vasoactivity 
The expression profile suggests GPR81 is involved in vascular and 
microvascular function, as described for other GPCRs with metabolic 
intermediates. For example, niacin, which activates GPR109a, reduces the 
production of reactive oxygen species by arterial endothelial cells138 and also 
promotes vasodilation by stimulating prostaglandin production139. Succinate 
activation of GPR91, which like GPR81 is coupled to Gi, acutely increases BP 
in rats142 and has direct effects on arterial contractility143. For lactate/GPR81, 
however, functional data are limited. Increasing lactate concentration in the 
brain, either through exercise or by exogenous administration, promotes 
angiogenesis42. This effect is GPR81-dependent since lactate-induced 
angiogenesis does not occur in knockout mice. Lactate also vasoconstricts rat 
retinal microvessels92 but it is not known whether this is GPR81-mediated or 
relates to other actions of lactate on cell membrane transporters92. Infusion of 
very high concentrations of lactate increases BP in rats89 but this most likely 
reflects the sympathoexcitation induced by panic, rather than activation of 
GPR81 in blood vessels92. I have shown that in vivo GPR81 activation causes 
a rapid increase in BP, a reduction in blood flow to the kidneys, decreased 
GFR and no change in tubular reabsorption. I have also shown that the blood 
pressure effects of GPR81 activation are dependent on ETRA. Receptor 
activation of ETRA in the kidneys by ET-1 has directly comparable effects to 
GPR81 with vasoconstriction of both the afferent and efferent arterioles 
confirmed as well as decreased glomerular filtration and decreased blood flow 
to the kidney through ETRA181.  
 
The cellular mechanism underpinning GPR81-mediated vasoconstriction via 
ETRA is not known. In adipocytes, GPR81 couples to Gi, downregulating 
cAMP production and protein kinase A signaling141. Activation of Gi pathways 
in vascular smooth muscle cells, by GPCR kinase 5 for example, lowers 
intracellular cAMP, enhances vasoconstriction and causes sustained 
hypertension144. Similarly, activation of A1 receptors by adenosine constricts 
the renal afferent arteriole by a Gi-mediated cascade which activates 
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phospholipase C145. Reciprocally, agents that increase cAMP promote arterial 
vasorelaxation147,148. However, my data suggests the vasomotor effects of 
GPR81 activation are indirect, mediated by ETRA vasoconstriction. The 
mechanism by which this occurs is dependent on the cell type where GPR81 
is activated and where ET-1 is being released from. The majority of ET-1 is 
produced and released from endothelial cells. In response to an external 
stimulus, which act to either increases intracellular calcium or cAMP levels150, 
ET-1 is released from Weibel-Palade bodies and activates ETRA on VSM 
cells. ET-1 is also synthesised and secreted from VSMC where it is able to 
alter vascular responsiveness111,112,182. It is possible that activation of GPR81 
in VSMC promotes ET-1 production within the same cell as an inverse 
relationship between intracellular cAMP and myocyte ET-1 production is 
established160,161,162. However, the rates at which VSMC can produce ET-1 are 
around 1,800 times lower than that of endothelial cells in isolated aortae113 
suggesting that this is insufficient to cause such a rapid and pronounced BP 
response. Another option is that GPR81 is activated on endothelial cells and 
causes direct release of ET-1 from Weible-Palade bodies, however, as 
previously mentioned, these storage vesicles degranulate and release their 
contents in response to increased intracellular cAMP183 where as GPR81 
activation decreases cAMP levels. The most probable cellular mechanism, 
given the increase in plasma ET-1, is that GPR81 in smooth muscle 
communicates with the endothelial cell to enhance release of ET-1 by the 
constitutive pathway101. A strategy to further understand this would be to utilise 
conditional ETRA knock out mice, be that on endothelial and smooth muscle 
cells and repeat the experiments carried out here. 
 
There is a range of data that states that lactate and hypoxia cause 
vasodilation, in particular on vessels which are already constricted90–92. The 
mechanism by which lactate or hypoxia causes vasodilation has been shown 
to be independent of endothelial cell presense90, suggesting a differing 
pathway to that of GPR81 mediated vasoconstriction. It has been 
hypothesised that lactate, via GPR81, may serve to constrict blood vessels 
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when energy supplies are ample but in response to local metabolic need can 
switch to vasodilation once stores are restricted. I suggest that these are by 
two different intracellular mechanisms, one which involves ET-1 release from 
endothelial cells and the other by a currently unknown pathway.  
 
6.3 GPR81 as a therapeutic target 
It is well known that renal ischemia reperfusion injury (IRI) increases internal 
extracellular lactate concentrations184. A unilateral model of IRI with 
contralateral nephrectomy was carried out in adult male Gpr81-/- mice and 
wildtype littermates by my collaborators as AstraZeneca and I was provided 
with a proportion of frozen kidney to assess whether global genetic deletion of 
the receptor was protective. I selected a panel of transcriptional markers to 
capture cardinal features of IRI, demonstrating the anticipated increase in KIM-
1, col1a1, TNF and F4/80 expression in wild-type mice. In contrast, Gpr81-/- 
mice demonstrate renoprotection, with significantly lower induction of the 
markers of tubular injury, fibrosis and inflammation (Figure 6.3). It is possible 
that increased lactate in IRI binds to GPR81 causing increased renal 
vasoconstriction which induces damage, therefore preventing this injury may 
have beneficial effects in kidney injury. 
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Figure 6.3 Gpr81-/- mice are protected from renal ischaemia reperfusion injury 
Male adult Gpr81-/- mice and wildtype littermates underwent sham surgery or left renal 
IRI for 27 minutes with a contralateral right kidney nephrectomy. After 7 days, mice 
were culled and tissues collected. Gene expression was measured in cDNA from left 
kidneys by qPCR which was all normalised to housekeeper gene Hprt. Data are 
mean±SEM, n=4-6 and statically analysis was carried out using one-way ANOVA with 
multiple comparisons.  
 
Similar beneficial outcomes are reported in cerebral ischaemic injury: 
overexpression of GPR81 amplifies sensitivity to ischaemic injury in a neuronal 
cell line; 3-hydroxy-butyrate, which antagonises GPR81, prevents lactate-
induced injury in primary cultured neurons and is neuroprotective in mice 
exposed to cerebral artery occulsion72. My study does not establish the 
mechanism of renoprotection in Gpr81-/- mice. Based on my data, a plausible 
hypothesis is that deletion of the receptor prevents sustained vasoconstriction 
following injury. Certainly, renal IRI has a strong haemodynamic component185 
and strategies preventing sustained vasoconstriction may offer beneficial 
vascular support in the post-injury phase186. The Home Office project licence 
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under which these studies were performed did not include the use of the IRI 
model and therefore extensive investigation into the mechanisms behind this 
protection were not possible during my PhD. However, I have established that 
GPR81 mediated vasoconstriction acts in an ETRA dependent manner and 
therefore blockade of this pathway should have similar results to GPR81 knock 
out. In fact, it has been previously shown that unilateral IRI in CD-1 mice 
causes an increase in ET-1 protein and mRNA expression alongside an 
increase in ETRA (but not ETRB) mRNA levels184. Gene deletion of ET-1 from 
vascular endothelial cells has been shown to significantly protect from a range 
of renal injury parameters in a bilateral mouse model of IRI187. ETRA has been 
targeted as a potential therapy in AKI using renal injury models. Specific ETRA 
antagonist BQ-123 in a rat model of kidney transplantation showed reduced 
renal reperfusion injury with less tubular and glomerular injury compared to 
controls. In the same way, a similar antagonist, Atrasentan, in a mouse model 
of unilateral IRI showed reduced microvascular injury and prevented renal 
mass reduction. As these drugs are already used by clinicians and are 
reasonably well tolerated, targeting ETRA directly rather than via GPR81, 
which I would expect to have similar outcomes, is a more promising 
therapeutic strategy185. 
 
The off target pressor effects of GPR81 activation mean that this is no longer 
a plausible target for the treatment of dyslipidemias and AstraZeneca have 
therefore closed their project on this. I believe the future of cardiorenal GPR81 
research is in the potential protective role of gene deletion or antagonism in a 
range of renal or cardiac injury settings along with a more advanced 
understanding of the interactions with the endothelin system.  
 
In summary, my PhD studies have indicated that GPR81 activation regulates 
macro- and microvascular perfusion within the kidney, dependent on ET-1 
signalling by ETRA. The physiological requirement for such a system is not 
clear since this would vasoconstrict regions of high anaerobic cellular 
metabolism. Earlier work associating exercise-induced accumulation of 
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extracellular lactate in skeletal muscle with the release of ET-1 into the 
circulation163 provides some insight. Here it was proposed that ET-1 release 
helped to maintain systemic BP during exercise163. My studies suggest a 
mechanistic link and it may be that GPR81 activation constrains and regulates 
flow into relatively ischemic areas of the kidney, militating against hyperaemic 
damage. When ischemia is sustained, blockade of the GPR81 system or 
ETRA directly, could be therapeutically tractable to offer vascular support and 
reduce renal injury. 
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